

**SCHISTOSOMIASIS: THE DISEASE, ANTI-SCHISTOSOMA VACCINE
CANDIDATES AND BABOONS AS IDEAL MODELS IN SCHISTOSOMIASIS
STUDIES**

ABSTRACT

Schistosomiasis is a parasitic disease caused by blood flukes of the genus *Schistosoma*. Acute schistosomiasis (Katayama's fever) may occur weeks after the initial infection, especially by *S. mansoni* and *S. japonicum*. Manifestations include fever, cough, abdominal pain, diarrhea, hepatosplenomegaly and eosinophilia. Pathology is due to host response to antigens released by the *Schistosoma* eggs lodged in tissues. Chronic infection may cause granulomatous reactions and fibrosis in the affected organs, which may result in manifestations that include: colonic polyposis with bloody diarrhea; portal hypertension with haematemesis and splenomegaly; cystitis and ureteritis with hematuria, which can progress to bladder cancer; pulmonary hypertension; glomerulonephritis; and CNS lesions. Cerebral granulomatous disease may be caused by ectopic *S. japonicum* eggs in the brain, and granulomatous lesions around ectopic eggs in the spinal cord from *S. mansoni* and *S. haematobium* infections may result in a transverse myelitis with flaccid paraplegia. At present the most effective control method is chemotherapy with use of praziquantel as the drug of choice. With the possibility of drug resistance and re-infection, the focus is on development of vaccine(s) that can significantly reduce the incidence of the disease. Many different *Schistosoma* antigens that are capable of protecting experimental animals against schistosomiasis have been identified. The potential of these vaccine candidates need to be validated fully in humans. As a starting point, the antigens need to be tested in an animal model that is biologically and immunologically closely related to humans. The baboons may be the ideal models for this purpose as prelude for human clinical trials. This article reviews the disease schistosomiasis; anti-schistosoma vaccine candidates; and also looks at baboons as ideal models in schistosomiasis studies.

Key words: Antigens; Baboons; Control; Model; Pathology; Praziquantel; Protection; Resistance; Schistosomiasis; Snails; Vaccine; Vector

Introduction

Schistosomiasis also known as bilharzia, bilharziosis or snail fever is a parasitic disease caused by several species of fluke of the genus *Schistosoma*, which affects human beings, domestic livestock and wild animals including non-human primates (Pearce, 2003). The disease is a major health hazard in tropical countries, especially in areas with water that is contaminated with freshwater snails which may carry the parasites. It is estimated to affect between 200 and 300 million people, particularly children who may acquire the disease by swimming or playing in infected water (Anon., 1993). More than 80% of those infected are in sub-Saharan Africa, where it is a poverty related health problem and a major cause of morbidity (Chitsulo *et al.*, 2000).

The parasites cause chronic morbidity in large numbers of infected individuals, with severe life threatening consequences in a small percentage of those affected. Although it has a low mortality rate, schistosomiasis often is a chronic illness that can damage internal organs and in children impair growth and cognitive development. It is estimated that 280,000 people die from this disease in sub-Saharan Africa each year (van der Werf *et al.*, 2003), and 4.5 million disability-

adjusted life years (DALYs) lost on account of schistosomiasis world-wide (Anon., 2002). Schistosome infections may also be impacting the etiology and transmission of HIV/AIDS, TB and malaria, and vice versa (Kallestrup *et al.*, 2005; Brown *et al.*, 2006). In particular, the interaction between schistosomiasis and HIV/AIDS is receiving increasing attention, given the role of immune responses in both diseases and the geographic overlap in distribution; low CD4⁺ T-cell counts resulting from HIV infection may increase susceptibility to schistosome infection and influence egg excretion (Gryseels *et al.*, 2006).

A number of *Schistosoma* species have been reported to affect humans and other mammals (Farah *et al.*, 2000), but only three are of significant importance in human schistosomiasis; *Schistosoma haematobium*, *S. mansoni* and *S. japonicum* (Cheesbrough, 1985). *S. haematobium* causes urinary schistosomiasis and occurs in Africa, Asia and Europe (Anon., 1993). *S. mansoni* which cause intestinal schistosomiasis occurs in Africa, South and Central America, while *S. japonicum* the other causative agent of intestinal schistosomiasis is restricted to the Far East countries such as Philippine, China, Thailand, Laos and Cambodia (Anon., 1993). Other species, such as *S. intercalatum* and *S. mekongi* also affect humans, but to a lesser extent. Species such as *S. bovis*, *S. curassoni*, *S. margrebowiei*, *S. matheei* and *S. rhodhiani* infect animals but may also infect human being on rare occasions (Sturrock, 2001).

Schistosomiasis is endemic in 74 countries globally, and in Africa it is endemic in 46 out of 54 countries (Boelee and Madsen, 2006). More than 50% of morbidity /pathology cases associated with *S. mansoni* are found in Tanzania, DR Congo, Nigeria and Kenya. Sudan and Somalia have very low endemicity for *S. mansoni*. *Schistosoma haematobium* infections are low in Ethiopia, Uganda and Madagascar (prevalence $\leq 1\%$). Burundi, Rwanda, Equatorial Guinea and Eritrea have also very low endemicity for *S. haematobium* (van der Werf *et al.*, 2003). But establishment of irrigation and other water resource development projects, increase in population, resettlement/migration, and diseases in Africa have increased transmission, and also made it possible for schistosomiasis to spread to areas where it was not common (Boelee and Madsen, 2006; Gryseels *et al.*, 2006; Li *et al.*, 2007). The Diama dam on the Senegal River introduced *S. mansoni* to Mauritania and Senegal (Gryseels *et al.*, 2006). Egypt's Aswan Dam helped to eliminate *S. haematobium* from the Nile Delta but aided in establishing of *S. mansoni* in Upper Egypt. *S. mansoni* was introduced into Somalia and Djibouti due to population disarticulation (Gryseels *et al.*, 2006). Schistosomiasis and other water related diseases may become more acute as a result of the growing human population, and the ensuing demands on energy and food that will lead to expanded and intensified exploitation of water resources in Africa (Boelee and Madsen, 2006).

In Kenya, where about 1.5 Million people are affected with schistosomiasis, the species are; *S. haematobium* and *S. Mansoni* (van der Werf *et al.*, 2003). *S. haematobium* is found in the coastal counties, eastern and western Kenya (King *et al.*, 2003), but *S. mansoni* is mainly found in Central and Western regions of Kenya (Highton, 1974; van der Werf *et al.*, 2003).

Diagnosis of schistosomiasis

Microscopic identification of eggs in stool or urine is the most practical and standard method for diagnosis (Feldmeier and Poggensee, 1993). Stool examination is performed when infection with *S. mansoni* or *S. japonicum* is suspected and urine examined when *S. haematobium* is suspected. Eggs are identified by size and shape (Gryseels *et al.*, 2006). Eggs can be present in the stool in infections with all *Schistosoma* species. The tests may be negative during the migration phase proceeding egg excretion (Anon., 2014). Since eggs may be passed intermittently or in small amounts, their detection can be enhanced by repeated examinations and/ or concentration

procedures (Elliott, 1996). The egg out-put can also be quantified by use of Kato-Katz technique or the Ritchie technique. Tissue biopsy (rectal biopsy for all species and urinary bladder biopsy for *S. haematobium*) may demonstrate eggs when stool and urine examinations are negative. Several widely used immunological methods are available for schistosomiasis antibody detection. The most important ones are the indirect immunofluorescence test (IFT), the indirect haemagglutination test (IHAT) and the enzyme-linked immunosorbent assay (ELISA). ELISA is the commonly used test for the serological detection of *Schistosoma* infection, particularly in the diagnosis of egg-negative cases (Anon., 2014).

Molecular assays offer high sensitivity, which is important in the context of low parasitic loads as observed in low transmission setting. These assays can be useful to identify species (species specific DNA amplification), determine the origin of the parasite by comparing the results with the international gene sequence databases, and assess unique or multiple introductions in a transmission focus. Real-time PCR is an alternative method for quantifying parasitic load. In addition a 28S rRNA gene based nested PCR assay has been used to define *Schistosoma* species in migrants and international travellers (Cnops *et al.*, 2012).

The morphology and life cycle of the parasites

The males of *S. mansoni* are creamish in colour, broader, bear a gynaecophoric canal and measure 6-12mm long with a diameter of 1.1mm. The number of testes varies from 4-13 and these are anteriorly placed (Cheesbrough, 1981). The morphology of male *S. haematobium* is similar to that of *S. mansoni* except it is longer. *S. japonicum* has also similar morphology to *S. mansoni*, but like *S. haematobium* it is longer and narrower. The females of the three species are darker, slender and relatively larger than the males, measuring 10-20mm long by 0.6mm wide (Yole, 1996).

The eggs of *S. haematobium* have a terminal spine, while those of *S. mansoni* and *S. japonicum* have lateral spine (Cheesbrough, 1981). The eggs of *S. mansoni* and *S. japonicum* are laid by the female adult worms in the mesenteric blood vessels from where they penetrate into lumen of the intestines of the definitive hosts and are passed out with faeces (Cheever and Andrade, 1967). *S. haematobium* eggs are passed out in urine, rarely in faeces because they are laid in the walls of the urinary bladder (Cheesbrough, 1981). Humans get infected after recreational or occupational contact with freshwater that has free-swimming cercariae. The main types of exposure to infected water are connected to agricultural, fishing, domestic and recreational activities (Anon., 2014).

Mature eggs once passed with faeces or urine in fresh water hatch into female and male miracidia, under condition of light and warmth (Kassim and Gilberton, 1976). A miracidium swim actively by means of cilia until it encounters an appropriate snail or die within 48 hours. Penetration into the vector snail is through the soft parts of the body and is achieved by secretions from the anteriorly placed penetration glands of the parasite (Jourdane and Theron, 1987). Once inside the snail, miracidia lose their ciliated epidermal layer and develop into mother sporocysts (Cheesbrough, 1981). A further asexual multiplication takes place to yield the final larval stage, the cercariae, which are shed from the snail between 4-6 weeks after infection depending on light and temperature (> 20-25°C) (Yole *et al.*, 1996; Anon., 2014). The optimum temperature for infection of the snails ranges from 20-30°C, which explains the tropical and subtropical distribution of schistosomiasis. Cercarial shedding occurs mainly during the warmest hours of the day, and one snail can shed about 1000-2000 cercariae daily, but these numbers decrease with time. The cercariae in fresh water can swim for about 72 hours, and when they come into contact with wet skin of the host, they penetrate between the hair follicles (Jourdane

and Theron, 1987; Anon., 2014). The penetration process takes 5-15 minutes and cercariae lose their tails and become schistosomula (Bustindy and King, 2009).

The schistosomula enter the peripheral lymphatic or venous vessels and are carried to the lungs via the heart and appear in the lungs 4-7 days after penetration. From the lungs they move to the portal vessels via the heart, where they grow into male and female adult worms (Anon., 2003). The adults, male and female then pair up, and remain in copula with the female lying in the gynaecophoric canal of the male. In this state, the worm pairs migrate to their ultimate vascular bed, specifically, superior mesenteric veins (*S. mansoni*), inferior mesenteric and superior hemorrhoidal veins (*S. japonicum*), or the vesical plexus and veins draining the ureters (*S. haematobium*) where the females begin to lay eggs. A proportion of the eggs of *S. japonicum* and *S. mansoni* are carried to the lumen of the colon and removed through faeces. But the eggs of *S. haematobium* are concentrated in urine (Cheever, 1969; Anon., 2014). The life cycle continues when eggs come into contact with fresh water and hatch into miracidia (Lyons, 1978; Anon., 2003). Figure 1 detail the life cycles of three species of schistosome.




Figure1. The life cycle of *Schistosoma* parasites: adapted from Center for Disease Control. Laboratory Identification of Parasites of Public concern, 2nd edition, 2003.

Host preference and tissue localization of *Schistosoma*

Schistosoma mansoni affect humans and non-human primates (Sturrock *et al.*, 1978). Many primates are naturally infected. Miller, (1960), found out that in endemic areas, baboons, vervets and sykes are affected, suggesting presence of a true zoonosis. The parasites may also develop to maturity in a number of experimental animals, referred to as permissive hosts. These hosts include mice, hamsters and Rhesus monkeys. Rodents such as rats are rarely infected (Kuntz *et*

al., 1971; Cheever *et al.*, 1974). The hosts for *S. japonicum* are humans and other mammals. Humans are considered to be the only reservoir of *S. haematobium* (Anon., 2014).

Snails of various groups act as intermediate hosts for different species of *Schistosoma* (van der Werf *et al.*, 2003). The geographical distribution of the snails, therefore influence the endemicity of the parasite. *S. mansoni* is transmitted by species of the genus *Biomphalaria*. In East Africa; *Biomphalaria pfeifferi* is the vector (Lyons, 1978). *S. haematobium* and *S. intercalatum* are transmitted by *Bulinus* species. In Kenya, *Bulinus africanus* and *B. truncatus* complex are the vectors for *S. haematobium* (Anon., 2014). *S. japonicum* is transmitted by *Oncomelania* species and *S. mekongi* by *Neotricula* species (Gryseels *et al.*, 2006). Snails live in well aerated water with vegetations. The vegetation serves as food and also supply leaf surface for egg deposition. Although snails can survive at higher temperatures, they thrive well at an optimum temperature range of 22-26°C. Snail population decreases during the rainy season and increases in the drier and warmer months of the year. However, where water temperatures are more stable, some snail population, show no seasonal trends. But droughts and floods reduce their populations (Brown, 2005).

In tropical lakes the extraordinary growth of certain species of floating plants, particularly *Eichhornia crassipes* (water hyacinth), *Salvinia auriculata* (water fern) and *Pistia stratiotes* (water lettuce), provide rich support for multiplication of vector snails, especially *Bulinus* and *Biomphalaria* species, and of insects (Anon., 1993). Snail dispersal along water-courses is also assisted by floating islets of vegetation. The spread of water hyacinth is having a severe economic impact on Eastern African lakes. Submerged vegetation, of which *Ceratophyllum demersum*, *Polygonum senegalense* and *Utricularia inflexa* are examples, may support large snail colonies, especially when the aquatic plants are growing vigorously. As it sometimes occurred in Lake Nasser, bottom algae can support a snail population that ensures the transmission of schistosomiasis (Anon., 1993).

Pathology

The parasitological and pathological changes due to acute and chronic schistosomiasis in humans, non-human primates and mice have been documented (Warren, 1966; Sadun *et al.*, 1966; Cheever and Andrade, 1967; Myers *et al.*, 1970). Baboons infected with *S. mansoni* develop similar signs of acute human schistosomiasis, including eosinophilia and fever (Damian *et al.*, 1992). The immune responses that develops following infection with schistosomiasis often proceeds to cause pathological changes that are primary cause of the illness (Kariuki and Farah, 2005). The pathology of schistosomiasis may be divided into three main stages. These stages include; the invasion phase, the maturation of infection and the chronic phase of the disease. The invasion phase is the actual penetration of the definitive host by the cercariae and the following 2-7 days during which the cercariae migrate from the skin to the lungs (Cheesbrough, 1981). This phase is marked by a moderate to intense skin reactions called "Swimmer's itch" at the site of penetration depending on individual's sensitivity to the parasites (Capron and Capron, 1994). Individuals in endemic areas show little or no reaction, while visitors develop marked skin rashes and urticaria (Clarke *et al.*, 1970).

The acute phase starts 6-12 weeks after infection, and coincides with peak egg deposition and the characteristic pathological manifestation in this stage, in moderate and heavy infections is an acute febrile reaction often referred to as the "Katayama syndrome" (Clarke *et al.*, 1970). The symptoms includes; fever, fatigue, urticaria, cough and asthma-like symptoms. The eggs produced induce an inflammatory reaction in the liver and walls of the colon and rectum, with formation of granulomas where giant and epithelioid cells infiltrate around the egg and held

together by an extra cellular matrix (Farah *et al.*, 1997). The clinical signs at this stage are; abdominal pain and tenderness and intermittent dysentery or diarrhoea (King and Mohmoud, 1998). The intestines may have serosal nodular lesions called “Sandy patches” or in severe cases polyps leading to pseudo-tumours or bilharziomas (Cheever and Andrade, 1967). There is also a remarkable enlargement of the mesenteric lymph nodes (Clarke *et al.*, 1970).

Histologically, the acute granuloma is seen to consist of a centrally placed *Schistosoma* ovum surrounded by concentric layers of inflammatory cells, predominantly eosinophils (Lenzi *et al.*, 1987). Lymphocytes, macrophages, plasma cells and neutrophils are also present in the granulomas. The chronic phase which is a sequel to modulation of the granulomatous inflammation, is characterised by reduction in granuloma size and diminished cellular infiltration particularly eosinophils. This stage is largely sub-clinical, but it contributes to long term debility associated with chronic schistosomiasis (Mitchnson and Oliviera, 1986).

In some cases of schistosomiasis, the granulomas may fail to modulate resulting in the hepatosplenic disease (Wyler and Telebian, 1997). This is the main cause of schistosomiasis related mortality. The reaction to the eggs in the liver may eventually cause the peri-portal fibrotic reaction known as “Symmers clay pipe stem fibrosis” which may lead to formation of varicose around the rectum, stomach and oesophagus (Andrade, 1987). In other cases the eggs can be lodged in the brain, spinal cord, lungs and the kidneys. Neurological schistosomiasis is due to eggs being trapped in the brain or spinal cord (Pittella and Lana-Peixoto, 1981), and renal schistosomiasis manifest as nephropathy or glomerulonephritis (Andrade, 1987). Death due to *S. mansoni* infection is as a result of haematemeses, portal hypertension and occasionally upper gastro-intestinal haemorrhages (Dessein, 2003; Dune, 2003). Figure 2 and 3 show the histopathology in the liver and colon of baboons due to *S. mansoni* eggs.

Schistosoma haematobium in endemic settings affects mostly children of 5-15 years old. The skin penetration may also cause skin eruption and pruritus. The parasites migrate through blood to reach the venous plexuses and mature to the adult stage. During the first month of infection, a non-immune individual can present with general immune-allergic reactions during migration phase and early egg deposition (Anon., 2014). Only a small proportion of cases will progressively develop chronic symptoms, which are more likely in people with heavy infections and recurrent exposure as seen in endemic settings. The infection can remain pauci-symptomatic for a long period but still cause progressive damage to the urogenital tract (Anon., 2014).

The chronic stage of the infection of *S. haematobium* corresponds to urogenital complications as the female worm releases eggs which migrate through the wall of the bladder and the urogenital system. These retained eggs provoke a granulomatous inflammatory response, which is the main cause of pathology in the human host. While medical complications are progressive, microscopic haematuria is an early sign that should be investigated for individuals with known exposure to the parasite. Haematuria and dysuria are the main symptoms of urogenital schistosomiasis, and early complications are infections of the upper and lower urogenital tract and lithiasis (Anon., 2014). Chronic infections are characterized by long term complications such as obstructive and fibrous lesions of the urogenital tract, chronic cystitis, calcification in the bladder and renal impairment. *S. haematobium* is considered a risk factor cancer of the urinary bladder in endemic settings (Anon., 2014).




Figure2. Liver and large intestine of a baboon infected with *S. mansoni*. **A:** Section of liver showing a large portal egg-granuloma with an ovum surrounded by large numbers of eosinophils, neutrophils, histiocytes and lymphocytes. **B:** Section of the colon of same baboon having many *S. mansoni* eggs and infiltrated with inflammatory cells.

288

289




Figure3. The liver and colon of baboon infected with *S. mansoni*. **A:** Liver section showing egg-granuloma surrounded with inflammatory cells, mainly mononuclear cells and a few eosinophils. The granuloma is small. **B:** Section of the colon of same baboon showing an ovum, and also infiltrated with inflammatory cells.

Immune responses to *Schistosoma* infection

All stages of *Schistosoma* induce a very pronounced immunological response, with the more predominant being directed against the eggs (Omer-Ali *et al.*, 1988). The adult worms are largely unaffected due to development of evasive mechanisms which enable the worms to survive in the hostile environment of the host (Dunne, 2003). These evasive mechanisms of the adult parasite include induction of anti-inflammatory molecules (Ramaswamy and Kumar, 2000), incapacitation of lymphoid cell function (Angeli *et al.*, 2001), coating of the host's surface antigens (Loukas *et al.*, 2001) and production of anti-oxidant enzymes among many other mechanisms (LoVerde *et al.*, 2004).

Schistosomula are the most susceptible to immune attack both in-vitro and in experimental murine models. The surface of a schistosomulum has glycoprotein antigens that share carbohydrate epitopes with large polysaccharide antigens in the parasite egg. These antigens induce IgE and IgG dependent cellular cytotoxicity reactions involving eosinophils, macrophages, platelets and complement mediated cellular cytotoxicity (Capron *et al.*, 1979; Gressner *et al.*, 1998). Infection with *S. mansoni* has been shown to elicit both the cellular and humoral arms of the immune response. Cellular immune response to *S. mansoni* infection in baboons is largely of mixed Th1/Th2 phenotype, similar to the situation in the human hosts (Mola *et al.*, 1999). Studies to determine the role of antibodies in the immune response in baboons have demonstrated IgM as the predominant antibody in the primary response, while the secondary response is characterised by production of other classes specifically IgG and IgE (Nyindo *et al.*, 1999).

Cytokine levels peak during acute *S. mansoni* infection, but decline with chronic infection and become almost undetectable after treatment (Mola *et al.*, 1999). Re-infection after treatment induces two to three fold increases in soluble egg antigen (SEA) specific interleukin-4 (IL-4), IL-5, IL-10, IL-2 and transforming growth factor β (TGF- β) production. SEA-induced IFN- γ production does not increase with re-infection after treatment, but induced TGF- β production remains elevated as the infection become chronic and correlates with diminished hepatic granuloma size, implying its participation in the down-modulation (Mola *et al.*, 1999). SEA in baboons also induces lymphocytes proliferation during the acute phase of the disease (Mola *et al.*, 1999).

Control of schistosomiasis

The main approaches that have been applied in an attempt to control schistosomiasis include; control of snail vectors, chemotherapy, improved sanitation, prevention of water contact and health education (Pearce, 2003). Molluscicides such as niclosamide have been widely used to control snails. However, this approach has several limitations. First, the chemicals are expensive and their application must be undertaken frequently. Some molluscicides are harmful for example sodium chlorophenate cause skin irritation and hence dangerous to the handlers. Molluscicides also kill some of non-target beneficial molluscs and other organisms such as fish. These disadvantages have largely limited the use of molluscicides, and make it necessary to opt for other methods to control snails (Klump and Chu, 1987; Anon., 2014). This is even important in areas where irrigation water is used intensively for fishing, livestock, domestic purposes and even drinking (Boelee and Laamrani, 2004; Nguyen-Khoa *et al.*, 2005).

Biological methods have also been tried. Birds and large snails such as *Marisa carmuarietus* and *Tarebia granifera* that feed on other snails have been used to control the vector snails (Yole, 1996). The other methods of control involves proper disposal of faecal and urinary waste in order to avoid contamination of the environment with *Schistosoma* ova (CairnCross and Feachem,

1983). The building of latrines would if practised ensure that this is achieved. But in practice, not every homestead in endemic areas has a latrine and in some cases the local population has cultural beliefs that are opposed to the use of latrines (CairnCross and Feachem, 1983).

Chemotherapy has been the only successful method in controlling schistosomiasis. The drugs currently available for treatment of schistosomiasis are praziquantel, metrifonate, oxamniquine and artemisinins (Richter, 2003). Praziquantel is the drug of choice and all species that cause pathology in humans and other animals are susceptible to it (Anon., 1998). Apart from the original product, generic praziquantel is also available and because of this, the price of the drug has come down considerably (Richter, 2003). The efficacy of oxamniquine and praziquantel is comparable, with a slightly better efficacy for praziquantel. Resistance to oxamniquine has however been observed in Brasil (Lambertucci *et al.*, 2000; Saconato and Atallah, 2000). Mirazid, the oleo-resin extract from myrrh of *Commiphora molmol* tree was established in Egypt as a novel drug against schistosomiasis and other parasitic diseases, but the drug is not being produced on commercial scale and its use is only confined to a few people in Egypt (Hamed and Hetta, 2005; Aly and Aly, 2006).

Even though schistosomiasis control can be approached with praziquantel alone, the possibility of developing resistance to this drug must be taken into account. This drug is effective against adult worms only, and has little or no effect on the eggs and immature worms. The preferred timing of follow-up is therefore 4-6 weeks after treatment. After a single dose of 40mg/kg body weight, 70-100% of the patients cease to excrete eggs (Anon., 2014). But under vigorous selection in the laboratory, it has been possible to demonstrate that some schistosomes possess the genes that carry a lesser susceptibility to praziquantel. Reduced cure rates have also been observed in Senegal due to very high re-infection rates with a relatively high number of developing immature parasite not susceptible to praziquantel (Stalma *et al.*, 1995; Fallon *et al.*, 1995; Anon., 1998; Kussel and Hagan, 1999). *S. mansoni* isolates that tolerate high doses of praziquantel have been characterized from Egyptians (Ismail *et al.*, 1996). The other problem is that in spite of recent reduction in price of praziquantel, the drug is still out of reach for many people in the endemic areas especially in Africa. Mass treatment does not also prevent re-infection (Richter, 2003; Kariuki and Farah, 2005). Re-infection occurs rapidly in exposed populations in most areas of endemicity such that within a period of 6 to 8 months following chemotherapy, the prevalence returns to its baseline level. Due to these reasons, it is clear that the most feasible long-term solution to schistosomiasis control is a protective vaccine (Pearce, 2003).

Anti-schistosome vaccine development

A reduction in worm numbers is the “gold standard” for anti-schistosome vaccine development, but as eggs are responsible for both pathology and transmission, a vaccine targeted on parasite fecundity and egg viability is also entirely relevant (Capron *et al.*, 2002). The effective vaccine should prevent the initial infection and reduce egg granuloma associated pathology (McManus *et al.*, 1998).

Recently, significant efforts have been made to develop a protective vaccine against *Schistosoma* infections, and several vaccine candidates have been identified (Ahmed *et al.*, 2001; Da'dara *et al.*, 2001; Zhang *et al.*, 2001; Dupre *et al.*, 2001; Capron *et al.*, 2001), but as the efficacy of any of these against schistosomiasis remains uncertain, the identification and characterization of novel anti-Schistosome vaccine molecules remains a priority (Hanem *et al.*, 2006). The development of vaccine remains an important move in the control of schistosomiasis (Hafalla *et al.*, 1999).

Vaccination with irradiated cercariae has consistently produced high levels of protection in experimental animals, but delivery problems, the need for a standardised product and safety considerations rule out this approach for use in human beings (Kariuki and Farah, 2005). However, it appears feasible to develop them for veterinary application. Nevertheless, many *Schistosoma* antigens continue to be tested as possible vaccines. These vaccine candidates may not be the final answer to controlling schistosomiasis, but may provide measurable protection and since morbidity rather than sterile immunity is the target, only partially protective vaccine is required (Bergquist, 1998). In view of the fact that the pathology in schistosomiasis is directly correlated to the number of *Schistosoma* eggs in the host, a vaccine can achieve its effect by offsetting parasite entry and development, and also by interfering with the production and delivery of eggs (Bergquist, 1998; Pearce, 2003).

In this review, we look at some of the major vaccine antigens for schistosomiasis and their protective efficacies. Those that were independently tested under the umbrella of the TDR/WHO committee in the mid-1990s that have been the focus of attention for many years are also discussed briefly in this review. A number of potentially promising vaccine antigens from *S. mansoni* and, to a lesser extent, *S. haematobium*, have been discovered and published, but only a few, namely, BILHVAX, or the 28-kDa GST from *S. haematobium* and Sm14 a member of Fatty acid binding protein (FABP) family from *S. mansoni* have entered clinical trials (Sh28 GST at Phase II and Sm14 at Phase I) (sponsored by Oswaldo Cruz Foundation- Brazil).

Vaccine candidates for *Schistosoma mansoni*

In mid 1990s under the coordination of UNDP/World Bank/ WHO special program for Research and Training in Tropical Diseases (TDR/WHO committee), six vaccine antigens from *S. mansoni*; Glutathione-S-transferase 28 (Sm 28-GST), paramyosin, Ir-V5, Triose phosphate isomerase (TPI), Sm 23 and Sm 14, were independently tested (Bergquist *et al.*, 2005). They yielded protective responses, but the stated goal of consistent induction of 40% or more protection was not achieved with any of tested antigens. The failure may be due to; a negative influence of insufficient antigen stability and the need to use standardized and effective adjuvant formulations or due to the fact that these antigens are not exposed onto the parasite surface, except Sm23 which is exposed on the apical membrane surface of the parasite, though not an abundant apical membrane protein on the parasite surface (Wright *et al.*, 1991). These antigens are not exposed to the host immune system and therefore do not induce the required protective responses in the host (Braschi and Wilson, 2006). The failure to develop an efficacious schistosome vaccine can also be attributed in part to the complex immunoevasive strategies used by schistosomes to avoid elimination from their intravascular environment (Pearce and MacDonald, 2002). Nonetheless, the following arguments are in support of possibilities of developing effective vaccines against the various schistosome species (Bergquist *et al.*, 2005): 1) as mentioned above, irradiated cercariae regularly induce high levels of protection in experimental animals, and additional immunizations boost this protection further, 2) humans in endemic areas develop various degrees of resistance, both naturally and drug-induced, and 3) antihelminth recombinant vaccines against cestode platyhelminths have been developed successfully and applied in veterinary practice (Craig *et al.*, 2007). Due to these arguments, a large number of schistosome antigens has been unearthed (utilizing the complete genome sequence), and additional candidates are now being found through proteomic and immunomic approaches.

Tetraspanins. These are four-transmembrane-domain proteins found on the surfaces of eukaryotic cells, including B and T cells. They have two extracellular loops; a short loop 1 of 17

to 22 amino acid residues (EC-1) with little tertiary structure and a larger, 70- to 90-amino acid residues loop 2 (EC-2), which has four or six cysteine residues that form two or three disulfide bonds. Although their functions are unknown, it is now apparent from proteomic studies that a family of tetraspanins is expressed in the schistosome tegument (Braschi and Wilson, 2006), and at least three of these show promise as vaccines. Sm23 is a tetraspanin expressed in the tegument of *S. mansoni* and is one of the independently tested WHO/TDR vaccine candidates (Bergquist and Colley, 1998). Sm23 has been shown to be the most effective when given as a DNA vaccine (Da'Dara, *et al.*, 2003), but not effective as a recombinant protein when formulated with alum. It induces 40-50% protection in mice (Bergquist *et al.*, 2002). Recently two new *S. mansoni* tetraspanins (SmTSP-1 and SmTSP-2) were discovered (Smyth *et al.*, 2003). Both proteins are expressed in the tegument membrane of *S. mansoni* (Tran *et al.*, 2006), and TSP-2 was identified as one of a subset of proteins that were biotinylated on the surfaces of live worms and subsequently identified using tandem mass spectrometry (Braschi and Wilson 2006). TSP-2 in particular produced high levels of protection as a recombinant vaccine in the mouse model of schistosomiasis, and both proteins were strongly recognized by IgG1 and IgG3 (but not IgE) from putative resistant (PR) individuals but not from chronically infected or unexposed individuals (Tran *et al.*, 2006). Both proteins induce good levels of protection (> 50% reductions in liver egg burdens) in immunized mice given an *S. mansoni* challenge. Knox, (2010), noted that TSP-2 provided protection in excess of 40% benchmark set by WHO for schistosome vaccine antigens to proceed to clinical trials. Another membrane-spanning protein, Sm29, has also been assessed as a vaccine candidate. Like TSP-2, Sm29 is preferentially recognized by antibodies from naturally resistant individuals compared with chronically infected individuals (Tran *et al.*, 2006), although the extent of selectivity is not as great as that reported for TSP-2. Studies in mice have shown that recombinant Sm29 is more effective (Loukas *et al.*, 2007). Other apical membrane proteins from the tegument that warrant attention as vaccines include the structural membrane proteins with large extracellular regions, such as annexin and dysferlin, and other proteins that are accessible to antibodies but with no homologues of known function, such as Sm200 (Braschi and Wilson, 2006). Murine DNA vaccination with gene encoding Sm200 induced 38.1% protection (Fonseca *et al.*, 2012).

SmTPI. The glycolytic pathway enzyme triose-phosphate isomerase (TPI) is found in each cell of each stage of the schistosome life cycle, and the *S. mansoni* enzyme (SmTPI) has long been targeted as a schistosomiasis vaccine candidate (Bergquist *et al.*, 2005).

Sm28/Sh28Glutathione-S-Transferase,GST. Sm28-GST is an enzyme expressed in subtegumental tissues of most developmental stages of the parasite (Porchet *et al.*, 1994). GSTs are thought to have detoxification role in the parasite. Vaccination of rats and hamsters with recombinant Sm28-GST resulted in significant reductions of worms (Balloul *et al.*, 1987). Trials in Primates demonstrated antifecundity effect (Boulanger *et al.*, 1999), and an anti-Sm28 monoclonal antibody showed antifecundity and anti-egg embryonation effects (Xu *et al.*, 1993). Clinical testing of Sh28-GST in people showed that vaccine was immunogenic and induced antibodies capable of neutralizing the enzymatic activity of the recombinant protein (Capron *et al.*, 2005). However, the data on the efficacy of this vaccine in phase II clinical trials are not available.

Sm-p80 Calpain. This is a calcium-activated neutral cysteine protease. The calpain large subunit was first discovered from *S. mansoni* by immunoscreening of a lambda phage cDNA library with sera from infected humans (Andresen *et al.*, 1991). Calpain is localized to the tegument surface and underlying musculature in adults and in the penetration glands and secretions of cercariae of

both *S. mansoni* and *S. japonicum* and is involved in surface membrane turnover (Siddiqui *et al.*, 1993) and associated with the inner tegument membrane (Braschi and Wilson, 2006). Calpain has been shown to be the target of a protective CD4⁺ T-cell clone that induce peritoneal macrophages from syngeneic recipients to kill schistosomula in vitro (Jankovic *et al.*, 1996). In addition, mouse recipients of this T-cell clone displayed significant resistance against cercarial challenge, making calpain the first vaccine antigen identified on the basis of T-cell reactivity.

The large subunit Sm-p80 calpain was expressed in baculovirus, and the semipurified protein induced 29 to 39% reductions in worm burdens (Hota-Mitchell *et al.*, 1997). Subsequent efforts to improve the efficacy of this vaccine have focused on DNA vaccine constructs, with and without Th1-type cytokine cDNAs, in mice and baboons (Siddiqui *et al.*, 2003). Sm-p80 antigen is a promising vaccine target because of its immunogenicity, protective efficacy and antifecundity effects observed in both experimental murine and non-human primate models of schistosomiasis (Zhang *et al.*, 2010). In VR1020, a vector approved for human use, an Sm-p80 based DNA vaccine formulation conferred 46% reduction in worm burden in an olive baboon (*Papio anubis*) model. These baboons also had a 28% decrease in egg production after challenge. The vaccine elicited robust immune responses to specific antigen Sm-p80, including IgG (it's subtypes IgG1 and IgG2), and IgA and IgM in vaccinated animals. When stimulated in vitro with recombinant Sm-p80, peripheral blood mononuclear cells and splenocytes from baboons vaccinated with Sm-p80-VR1020 produced higher levels of IL-2 and IFN- γ , the Th1 response enhancing cytokines, than IL-4 and IL-10 which are Th2 response enhancing cytokines. A mixed Th1/Th2 type of T-cell and humoral responses is generated after immunization with Sm-p80VR1020 (Zhang *et al.*, 2010). Prophylactic and antifecundity efficacies of Sm-p80 have been tested using a variety of vaccine approaches in both rodent and nonhuman primate models. Siddiqui *et al.*, (2014), evaluated the therapeutic efficacy of Sm-p80 using two different strategies and three Sm-p80-based vaccine formulations in baboons. Vaccine formulations were able to eliminate 10-36% of established adult worms; reduced retention of eggs in tissues from 10-57% and decreased the egg excretion in feces from 13-33%. The ability of Sm-p80 to provide cross-species protection against *S. haematobium* challenge has also been evaluated in hamster and baboon models. In hamsters vaccinated with recombinant Sm-p80 admixed with glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE), a reduction in worm burden (48%) and in tissue egg load (64%) was observed. But, in baboons, the Sm-p80/GLA-SE vaccine produced a 25% reduction in *S. haematobium* adult worms and decreased the egg load in the urinary bladder by 64%. The egg output reduction in feces and urine was 40% and 53%, respectively, in vaccinated baboons. A balanced pro-inflammatory (Th17 and Th1) and Th2 type of response was generated after vaccination and appears indicative of augmented prophylactic efficacy. These data on cross-species protection coupled with the prophylactic, therapeutic and antifecundity efficacy against the homologous parasite, *S. mansoni*, reinforces Sm-p80 as a promising vaccine candidate. It is currently being prepared for GMP-compliant manufacture and for further pre-clinical development leading to human clinical trials. These results solidify the expectation that the Sm-p80 vaccine may provide relief for both the intestinal and the urinary schistosomiasis and thus will be greatly beneficial in reducing the overall burden of schistosomiasis (Karmakar *et al.*, 2014).

Paramyosin (Sm 97). Paramyosin is a 97-kDa myofibrillar protein with a coiled-coil structure, expressed on the surface tegument of lung-stage schistosomula in the penetration glands of cercaria and may function as a receptor for Fc (Loukas *et al.*, 2001). The vaccine efficacy of paramyosin against *S. mansoni* was first described in the 1980s; mice immunized intradermally

with *S. mansoni* extracts and *Mycobacterium bovis* BCG adjuvant were significantly protected against subsequent infection, and antibodies predominantly recognized paramyosin (Lanar *et al.*, 1986). Vaccination of mice with native and recombinant paramyosin was then shown to provide modest (26 to 33%) but significant protection against challenge infection with *S. mansoni* (Pearce *et al.*, 1988).

Sm 22.6. This is also a tegumental protein. With its homologue in *S. japonicum* (Sj22.6), are involved in resistance to re-infection in endemic areas (Santiago *et al.*, 1998). Immunization of mice with recombinant 22.6 formulated with Freund adjuvant resulted in 34.5% reduction in worm burdens, but Sm 22.6 formulated with alum failed to induce any protection against schistosomiasis but elicited a regulatory response that was able to modulate allergic asthma in mice (Fonseca *et al.*, 2012).

SmFABPs. The *S. mansoni* fatty acid binding protein (FABP), Sm14, is a cytosolic protein expressed in the basal lamella of the tegument and the gut epithelium (Brito *et al.*, 2002). Sm14 has been assessed thoroughly as a recombinant protein vaccine and, to a lesser extent, as a DNA vaccine. Despite a high efficacy of recombinant Sm14 protein in mouse vaccine trials (Tendler *et al.*, 1996), Sm14 failed to induce protection levels of >40% when tested in other laboratories (Fonseca *et al.*, 2004) and as part of the WHO/TDR-sponsored trials. Co-administration of recombinant Sm14 protein with either IL-12 (Fonseca *et al.*, 2004) or tetanus toxin fragment C boosted protection. Immunization of mice with recombinant Sm14 expressed in *Mycobacterium bovis* BCG showed no induction of specific antibodies to Sm14, but splenocytes from vaccinated mice produced IFN- γ upon stimulation with recombinant Sm14. Moreover, mice that were vaccinated once with Sm14-BCG and then challenged with *S. mansoni* cercariae showed a 48% reduction in worm burden, which was comparable to that obtained by immunization with three doses of recombinant Sm14 protein (Varaldo *et al.*, 2004). Sm14 has entered human clinical trial (Phase I) in Brasil. The data on the efficacy of this vaccine in phase I clinical trials just as in the case of Sh 28 GST in phase II clinical trials are also not available.

Sm SOD, Sm GPX and Sm FILAMIN. Several studies of immunity in schistosomiasis, both in experimental models and human beings have shown that the larval stage is the most susceptible and the target for immune elimination (Smithers, 1982; LoVerde, 1998). The schistosomula elimination involves a cellular response that is potentiated by cytokines and/ or antibodies (Butterworth, 1984; LoVerde, 1998). Once the parasites mature to adult worms and reach the portal circulation, they are able to evade the engendered immune response of the host through the evolution of several defence mechanisms (Smithers and Terry, 1969; Maizel *et al.*, 1993; LoVerde, 1998). The host cells involved in cytotoxic response against the schistosomula produce reactive oxygen species such as superoxide anion and hydroxyl radicals capable of attacking the parasite apical membrane and initiating a lipid peroxidation that set off a chain reaction that results in the death of the parasite (LoVerde, *et al.*, 2004). The adult worms are able to evade immune elimination by expressing anti-oxidant enzymes Cu/Zn superoxide dismutase (SOD), Glutathione peroxidase (GPX) among other mechanisms (Callahan *et al.*, 1988; Mei and LoVerde, 1987). Hong *et al.*, (1992) and Mei and LoVerde, (1997) were able to demonstrate that the expression of these anti-oxidant enzymes are developmentally regulated such that the lowest gene expression and enzyme specific activity are in the larval stage and highest in adult worm. The anti-oxidant enzymes protect an organism from reactive oxygen species derived damage (James, 1994; LoVerde, 1998). These enzymes have been immuno-localized to the tegument and gut epithelia of adult worms (Mei and LoVerde, 1997).

To provide direct evidence that antioxidant enzymes are important in immune evasion and thus viable candidate vaccines, DNA vaccination strategies have been used to evaluate the efficacy of DNA constructs containing genes encoding *S. mansoni* Cu/Zn cytosolic superoxide dismutase (Sm-CT-SOD), Signal peptide-containing *S. mansoni* SOD (Sm-SP-SOD) and *S. mansoni* glutathione-S-peroxidase (Sm-GPX) in *S. mansoni* infection murine models. After use of different doses of plasmid cDNA constructs containing genes that encode these enzymes, mice exhibited a significant level of worm burden reduction when challenged with *S. mansoni* cercariae, with Sm CT-SOD showing 54%, and Sm-GPX 43.4% protection (Shalaby *et al.*, 2003). In addition to the anti-oxidant enzymes, Sm-filamin a structural protein has been identified as a vaccine candidate that also consistently induces significant levels of protection in murine model of schistosomiasis. The targets of protective response due to filamin vaccination seem to be the larval and adult stages of the schistosome parasite (LoVerde, 1998).

To demonstrate whether the protection observed in mice can be replicated in baboons as a prelude to human vaccine trails, the author and others tested these three vaccine candidates (SmCT-SOD, Sm GPX and Sm-filamin, all as DNA vaccines) in olive baboons [*Papio anubis*]. These vaccines were able to induce production of specific IgG against worm antigens, SEA and SWAP. CT-SOD and GPX showed slight anti-fecundity effect, but the reduction in the worm burden that had been reported in murine model was not observed in baboons vaccinated with these vaccines. These vaccines also did not alter the phenotype of the hepato-intestinal egg-associated pathology of *S. mansoni* infection in vaccinated baboons (no antipathology effect) (un-published report).

Vaccine candidates for *Schistosoma japonicum*

The leading *S. japonicum* vaccine candidates (as recombinant protein and/or DNA vaccines) are membrane proteins, muscle components, or enzymes. This review looks at some of the vaccine candidates for *Schistosoma japonicum* that have been identified recently, giving a brief mention of their characteristics and efficacies.

Sj26GST. The GSTs are a group of enzyme isoforms that catalyze the detoxification of lipophilic molecules by thio-conjugation. Some encouraging data are available for the protective efficacy of Sj28GST against *S. japonicum* in different mammalian hosts in China (McManus, 2005; Wu *et al.*, 2005). But recent work has focused on the 26-kDa isoform. Recombinant Sj26GST (rSj26GST) induces a pronounced anti-fecundity effect as well as a moderate but significant level of protection in terms of reduced worm burdens in mice, sheep, cattle, and pigs following challenge infection with *S. japonicum*. Similar levels of vaccine efficacy were obtained in water buffaloes vaccinated with purified rSj26GST (Wu *et al.*, 2005).

Paramyosin (Sj97). Native and recombinant paramyosin (Sj97) proteins confer protection against *S. japonicum* in mice, water buffaloes, and other mammalian hosts (Wu *et al.*, 2005). Furthermore, recent studies of human antibody isotype (Nara *et al.*, 2007) and Th2 cytokine responses to Sj97 add further support to this molecule as a leading vaccine candidate against *S. japonicum* (Leenstra *et al.*, 2006).

SVLBP. An *S. japonicum* very-low-density lipoprotein binding protein (SVLBP; molecular size, 20 kDa) is a membrane associated and located in the teguments and subteguments of adult male schistosomes (Fan *et al.*, 2003). In a study that used affinity-purified recombinant SVLBP (rSVLBP) to vaccinate mice, the worm numbers and egg numbers recovered from the veins and livers of the immunized mice reduced by 33.5% and 47.6% respectively (Gan *et al.*, 2005). The antibody response in vaccinated mice was greatly increased: the titers of IgG1, IgG2a, and IgG2b of the vaccinated group were significantly higher than those of the controls (Gan *et al.*, 2005).

SjTPI. Results of Chinese SjTPI (SjCTPI) plasmid DNA in mice have been good (Zhu *et al.*, 2002). Therefore, Zhu *et al.*, (2006) examined the transmission-blocking potential in larger animals by determining its vaccine efficacy in naive pigs. Pigs vaccinated with SjCTPI DNA had adult worm burdens reduced. The reduction was more on worm burdens, i.e., 53.6% for SjCTPI alone and 59.6% for SjCTPI plus IL-12. Vaccination with SjCTPI DNA reduced liver egg numbers by 49.4%, and this response was significantly enhanced by the addition of IL-12 (65.8% reduction in liver eggs). In addition to the dramatic protective effects seen in vaccinated pigs, it was also noted that granuloma size was reduced 42% in both groups. Coimmunization with a DNA plasmid of SjCTPI fused to heat shock protein 70 (SjCTPI-Hsp70) and IL-12 DNA induced protective immunity against experimental *S. japonicum* infection in water buffaloes (Yu *et al.*, 2006).

Sj23. Sj 23 is a tetraspanin integral membrane protein. The Chinese *S. japonicum* form (SjC23) has been shown to induce protection in mice as a synthetic peptide vaccine and as a plasmid DNA vaccine. Also induces protection in sheep, pigs, and water buffaloes. Vaccination with SjC23 DNA induces significant reductions in worm, egg burdens and the size of egg granulomas; thus, like SjCTPI, SjC23 produces an antipathology effect as well. The protective effect of the SjC23 plasmid DNA vaccine was enhanced with IL-12 in pigs (Zhu *et al.*, 2004) and mice (Gan *et al.*, 2005; Zhu *et al.*, 2004) and by a CpG immunostimulatory sequence in mice (Zhao *et al.*, 2005). As with the other candidate vaccines, extensive large animal field trials are now required to determine the precise protective potency of SjC23, with or without IL-12 or CpG.

Sj14. This is one of FABPs that are critical for schistosomes to take up fatty acids from host blood as essential nutrients and are thus prime targets for both vaccination and drug development. The 14-kDa FABP of Chinese *S. japonicum* (SjFABPc) has at least eight different variants encoded by a single-copy polymorphic gene, and it is particularly important to *S. japonicum* for uptake, transport, and compartmentalization of host-derived fatty acids, playing a vital role in the physiology and survival of the parasite. Several Chinese groups have obtained encouraging protection in mice by using SjFABPc, both as a recombinant protein and as a plasmid DNA vaccine.

Calpain. Immunization of BALB/c mice with purified recombinant *S. japonicum* calpain emulsified in complete Freund's adjuvant resulted in significant reductions in the number of recovered worms and also in egg production per female worm. In addition, raised levels of inducible nitric oxide synthase expression were observed in immunized mice, while adhesion of peritoneal exudate cells also occurred in the presence of sera from immunized mice, suggesting the involvement of both cellular and humoral protective mechanisms. In addition, spleen cells from the immunized mice showed enhanced production of IFN- γ by activated CD4⁺ T cells, and subsequent work with calpain-specific mouse T-cell hybridomas identified the T-cell epitope involved (Osada *et al.*, 2005). Localization studies have shown that calpain is present in the penetration glands and in the secretions of cercariae (Kumagai *et al.*, 2005).

DNA vaccination

The effectiveness of DNA vaccines against viruses, parasites and cancer cells has been demonstrated in animal models (LoVerde, 1998; Tuteja, 1999; Seder and Gurunathan, 1999). The DNA immunization induces both antigen-specific cellular and humoral immune response (Ramsay *et al.*, 1999; Alarcon *et al.*, 1999; Gurunathan *et al.*, 2000). DNA vaccination strategies include the incorporation of immuno-stimulatory sequences in the backbone of the plasmid, co-expression of stimulatory molecules, utilization of localization/secretory signals and utilization

of appropriate delivery system (Garmory *et al.*, 2003). The vaccines usually consist of plasmid vectors that contain DNA coding for a specific component of a disease-causing organism. The heterologous genes (transgenes) are inserted under control of a eukaryotic promoter, allowing protein expression in the mammalian cells (Davis, 1997). To optimize the efficacy of DNA vaccines an appropriate choice of plasmid vector should be used. The basic requirements for the backbone of DNA vector are; a eukaryotic promoter, a cloning site, a polyadenylation sequence, a selectable marker and a bacterial origin of replication (Gurunathan *et al.*, 1998).

With DNA vaccination, the actual production of immunizing proteins takes place in the vaccinated host. This eliminates any risk of infection that has been observed with some live and attenuated virus vaccines. Other advantages of DNA vaccines are; production of long lived immune responses, vaccines for multiple diseases can all be given in a single inoculation, all DNA vaccines can be produced using similar techniques, DNA vaccines are extremely stable and candidate DNA vaccine can be recovered from diseased tissues (Gurunathan *et al.*, 2000).

DNA vaccination against schistosomiasis has recently been investigated using a panel of plasmids encoding *Schistosoma* antigenic proteins such as Sj26 GST, Sj27 (Waine *et al.*, 1997; Zhou *et al.*, 1999; Zhang *et al.*, 2001), Sm-CT-SOD and Sm-GPX (Shalaby *et al.*, 2003), *S. japonicum* paramyosin (Yang *et al.*, 1995), Sm 23, 28 GST from *Schistosoma mansoni* (Dupre *et al.*, 1997), and Sm-p80 (Zhang *et al.*, 2010). Sj14 (Lui *et al.*, 2004), Sj23 (Gan *et al.*, 2005; Zhu *et al.*, 2004), Sm200 (Fonseca *et al.*, 2012) etc. the list is long.

By the use of techniques such as immunomics, genomics, proteomics etc, new target antigens are being identified, and alternative vaccination strategies to improve vaccine efficacy are also being explored. Extracellular vaccine candidates need to be expressed in bacteria or eukaryotic expression systems. Many of the selected targets are likely to require processing through the endoplasmic reticulum by virtue of their expression sites in the parasite (i.e., secreted or anchored in the tegument), and this may prove challenging. An additional important consideration is that antigen identification and successful protective results are of little value if GMP cannot be applied for scaling up of production of any vaccine candidate (Bergquist *et al.*, 2005). The selection of a suitable adjuvant and delivery system to aid in the stimulation of the appropriate immune response is a critical step in the path to the development and employment of successful anti-schistosome vaccines, and a number of approaches have been tested, with some success.

Baboon as an ideal model in schistosomiasis studies

A number of animal species have been used as models to study the basic biology, immunology and pathogenesis of schistosomiasis (Farah *et al.*, 2001). But the baboon is the most frequently used non-human primate in schistosomiasis research because of a multiplicity of qualities that make them more relevant models than rodents (Nyindo and Farah, 1999). Baboons are similar to humans in their anatomy, genetics and immunological responses (Villinger *et al.*, 2001). They acquire natural infections and are highly susceptible to experimental infections (Farah *et al.*, 1997). Baboons develop hepatic and intestinal pathology during the acute phase, modulate this pathology in chronic phase of the disease and acquire protective immunity as do humans (Farah and Nyindo, 1996; Farah *et al.*, 1997; Mola *et al.*, 1999; Nyindo *et al.*, 1999). In the wild, baboons show age-dependent prevalence of infection, with high rates of infection in juvenile baboons and young adults, a similar characteristic observed in humans (Fulford *et al.*, 1999). Baboons are also abundant especially in East Africa, and are not an endangered species. They adapt readily in captivity and to changes in their environment; can give birth twice in 18 months and live up to 20 years; and attain body weight of 20 kg (Farah *et al.*, 2000). It is also easy to

monitor the immune and disease progression in many different organs in individual baboons during the course of infection by performing some surgical manipulations (Mola *et al.*, 1999). Baboons acquire immunity on vaccination. For example, immunization with irradiated cercariae stimulates over 50% protection (Yole *et al.*, 1996) which is associated with elevated serum levels of schistosome-specific IgG and IgE. In addition, vaccination with irradiated cercariae results in reduction of the intestinal pathology (Farah and Nyindo, 1996). Some protection to challenge infection following vaccination with recombinant antigens has also been reported in baboons (Soisson *et al.*, 1993). The moderate size, possibility of repeated sampling, and ease of perfusion for recovery of adult worms make the baboon a good model for vaccine efficacy studies (Farah *et al.*, 2000). Baboons can also sustain repeated schistosome infections without any untoward lesions such as portal-caval shunting (Sturrock *et al.*, 1984) and with subsequent development of acquired immunity and increased resistance to re-infection. Such re-infection episodes are characterized by reduced adult worm burden and granulomatous inflammation (Mola *et al.*, 1999) which, as in humans, are associated with high serum levels of parasite specific IgE (Nyindo *et al.*, 1999). Therefore, for these reasons, vaccine candidates that have been tested in a baboon model and have shown encouraging results, such as those obtained with Sm-p80VR1020 DNA vaccination in baboons should be moved forward through development leading to human clinical trials.

There are however, a few constraints limiting the use baboons in schistosomiasis research, which include the high costs involved in trapping and maintaining them in captivity; the data from wild caught baboons may vary due to their heterogeneous genetic background; and immunologic reagents suitable for baboon work are currently lacking (Farah *et al.*, 2001).

Conclusion

Schistosomiasis is a chronic disease that is endemic in 74 countries in Africa, Asia and South America. Worldwide, an estimated 200 million people are infected, of which 20 million is assumed to suffer from more or less a severe form of the disease creating 4.5 million DALYs lost. Although it has a low mortality rate, schistosomiasis can damage internal organs and in children impair growth and cognitive development. It is estimated to kill 280, 000 people in sub-Saharan Africa each year. At present the most effective control method is chemotherapy with use of praziquantel as the drug of choice. With the possibility of drug resistance and re-infection, the focus is on development of a vaccine that can significantly reduce the incidence of the disease. Many different schistosome antigens that are capable of protecting experimental animals from challenge have been identified and many more will be identified. These antigens need to be standardized and effective adjuvant formulation(s) selected. The potential of these vaccine candidates need to be validated fully in humans. As a starting point, these antigens, as native, recombinant or cocktail DNA vaccines need to be tested in an animal model that is closely related to humans. As mentioned above, the parasite biology, the pathology, immune response and immunity to *Schistosoma* infection in humans differ significantly from the murine model of schistosomiasis but correlate better with the disease in baboons. Therefore, baboons may be ideal models for this purpose as prelude for clinical trials. Vaccines that show good results in baboons should then be moved forward to human clinical trials.

Conflict of Interest

The author declares that there are no conflicts of interest.

Acknowledgement

The author thanks the staff of the department of Medical Laboratory Science at Masinde Muliro University of Science and Technology for their encouragement, suggestions and technical support.

REFERENCES

1. Ahmed, H.M, Romeih,M.H., Sheriff, S.A, Fahim F.A., and Saber, M.A.(2001).Protection against *Schistosoma mansoni* infection with recombinant schistosomula 21.7 KDa protein. *Arab Journal of Biotechnology*, **24**: 229-249.
2. Alarcon, J.B. Waine, G.W.and McManus, D.P. (1999). DNA Vaccines: Technology and Application as anti-parasite and anti-microbial agents. *Advances in Parasitology*, **42**:343-410.
3. Aly, HF and Aly, SA. (2006). Essential role of *Citrus reticulata* and Mirazid in treatment of *S. mansoni* infected mice. Biochemical and Parasitological studies. *Polish Journal of Food and Nutritional Science*, **4**:461-467.
4. Amiri, P., Locksley, R. M., Parslow, T. G., Sadick, M., Rector, E., Ritter, D. and Mckerrow, J. H. (1992). Tumour necrosis factor alpha restores granulomas and induces parasite egg-laying in schistosome infected SCID mice. *Nature*, **356**:604-607.
5. Andrade, Z.A. (1987). Pathology of human schistosomiasis. *Memories do instituto Oswaldo Cruz*, Rio de Janeiro, **82**:17-21.
6. Andresen, K., T. D. Tom, and M. Strand. (1991). Characterization of cDNA clones encoding a novel calcium-activated neutral proteinase from *Schistosoma mansoni*. *J. Biol. Chem.***266**:15085-15090.
7. Angeli, V., Faveeuw, C., Roye, O., Fontaine, J., Teissier E., Capron, A.,Wolowezuk, I., Capron, M.and Trottein, F. (2001). Role of the parasite derived prostaglandin D2 in the inhibition of Epidermal langerhans cell immigration during schistosomiasis infection. *Journal of Experimental Medicine*, **193**: 1135 –1147.
8. Anonymous, Center for Disease Control (CDC). (2003). Laboratory Identification of Parasites of Public concern, 2nd edition.
9. Anonymous, European Centre for Disease Prevention and Control, ECDC (2014). Rapid Risk Assessment: Local Transmission of *S. haematobium* in Corsica, France
10. Anonymous, World Health Organization, WHO, (1990). Health education in the control of schistosomiasis. Geneva. *Schistosoma mansoni* observations on mechanisms and implication for control. *Immunological Investigation*, **21**: 391 – 407.
11. Anonymous, World Health Organization, WHO, (1993). The control of schistosomiasis, second report of the WHO expert committee.
12. Anonymous, World Health Organization, WHO, (1996).World Health Organization fact sheet. Geneva: WHO.
13. Anonymous, World Health Organization, WHO, (1998). Report on the WHO informal consultation on schistosomiasis control. Second report of a WHO expert committee. (WHO technical Report series no 830). Geneva. <http://who.ch/eds>
14. Anonymous, WHO (World Health Organization) Expert Committee. (2002). *Prevention and control of schistosomiasis and soiltransmitted helminthiasis*. WHO Technical Report Series No. 912, World Health Organization, Geneva,Switzerland: WHO.

15. Balloul, J. M., J. M. Grzych, R. J. Pierce, and A. Capron. (1987). A purified 28,000 dalton protein from *Schistosoma mansoni* adult worms protects rats and mice against experimental schistosomiasis. *J. Immunol.* **138**:3448-3453.
16. Bergquist, N. R., L. R. Leonardo, and G. F. Mitchell. (2005). Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? *Trends Parasitol.* **21**:112-117.
17. Bergquist, N.R. (2001), Schistosomiasis: from risk assessment to control. *Trends in Parasitology*, **18** (7): 309 – 314.
18. Bergquist, N.R. (1998). Schistosomiasis vaccine development. Progress and Prospects. *Memories do Instituto Oswaldo Cruz*, Rio de Janeiro, **93**: 95-101.
19. Bergquist, N.R.(1992). Present aspects of immunodiagnosis of schistosomiasis. *Memories do Instituto Oswaldo Cruz*, Rio de Janeiro, **87**: 29-38.
20. Bergquist, N.R. (1985). Controlling schistosomiasis by vaccination. A realistic option? *Parasitology Today*, **11**: 191-194.
21. Bergquist, N.R. and Colley, D.G. (1998). Schistosomiasis vaccines: research to development. *Parasitology Today*, **14**: 99 – 104.
22. Boelee E and Madsen H. (2006). Irrigation and Scistosomiasis in Africa: Ecological Aspects. Sri Lanka International water management Institute. 39p (IWMI Research Report 99).
23. Boelee, E and Laamrani, H. 2004. Multiple use of irrigation water in Northeastern Morocco. In *Beyond domestic: Case studies on poverty and productive uses of water at the household level*, eds. P. Moriarty; J.A. Butterworth; B. van Koppen. Delft, the Netherlands: IRC International Water and Sanitation Centre,
24. Boros, D.L. (1989). Immunopathology of *Schistosoma mansoni* infection. *Clinical Microbiology Review*, **2**: 250 – 269.
25. Boros, D.L., and Warren, K.S. (1970). Delayed hypersensitivity – type granuloma formation and dermal reaction induced and elicited by a soluble factor isolated from *Schistosoma mansoni* eggs. *Journal of Experimental Medicine*, **132**: 488-492.
26. Boulanger, D., A. Warter, B. Sellin, V. Lindner, R. J. Pierce, J. P. Chippaux, and A. Capron. (1999). Vaccine potential of a recombinant glutathione S-transferase cloned from *Schistosoma haematobium* in primates experimentally infected with an homologous challenge. *Vaccine*, **17**:319-326.
27. Braschi, S., and R. A. Wilson, R. A. (2006). Proteins exposed at the adult schistosome surface revealed by biotinylation. *Mol. Cell Proteomics*, **5**:347-356.
28. Brito, C. F., G. C. Oliveira, S. C. Oliveira, M. Street, S. Riengrojpitak, R. A. Wilson, A. J. Simpson, and R. Correa-Oliveira.(2002). Sm14 gene expression in different stages of the *Schistosoma mansoni* life cycle and immunolocalization of the Sm14 protein within the adult worm. *Braz. J. Med. Biol. Res.* **35**:377-381.
29. Brown D. (2005). Freshwater snails of Africa and their medical importance. 2nd Edition. London: Taylor & Francis.
30. Brown, M., G. Miiro, P. Nkurunziza, C. Watera, M. A. Quigley, D. W. Dunne, J. A. Whitworth, and A. M. Elliott. (2006). *Schistosoma mansoni*, nematode infections, and progression to active tuberculosis among HIV-1-infected Ugandans. *Am. J. Trop. Med. Hyg.* **74**:819-825.
31. Brunet, L. R., Finkelman, F. D., Cheever, A.W., Kopf, M. A., and Peace, E. J. (1997). IL-4 protects against TNT-alpha- mediated cachexia and death during acute schistosomiasis. *Journal of Immunology*, **159**: 777-785.

32. Bustindy AL and King CH. (2009). Schistosomiasis. In: Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ, Editors. *Manon's Tropical Diseases*. 23rd edition: Elsevier Saunders. 698-725.
33. Brunet, L. R. (1998). Cytokine interaction and immune responses during *Schistosoma mansoni* infection. *Parasitology Today*, **14**: 422 – 427.
34. Butterworth, A.E., Dunne, D.W., Filford, A.J., Thorne, K.J., Gachuhi, K., Ouma, J. and Sturrock, R.F. (1992). Human immunity for *Schistosoma mansoni*. Observations on mechanism and implications for control. *Immunological Investigation*, **21**: 391-407.
35. Cairncross, S. and Feachem, R.G. (1983). Environmental health engineering in the Tropics: An introductory text. New York, John Wiley and Sons.
36. Callahan, H.L.C., Crouch, R.K., and James, E.R. (1988). Helminth antioxidant enzymes: a protective mechanism against host anti-oxidants? *Parasitology Today*, **4**:218-225.
37. Capron, M. and Capron, A. (1994). Immunoglobulin E and effector cells in schistosomiasis. *Science*, **24**: 1876-1877.
38. Capron, M., Torpier, G. and Capron, A., (1979). Invitro killing of *Schistosoma mansoni* schistosomula by eosinophils from infected rats; role of cytophilic antibodies. *Journal of Immunology*, **123** (5): 2220 –2230.
38. Capron, A., Riveau, G., Bartley, P. and Mcmanus D.P. (2002). Prospects for a schistosome vaccine. Current drug targets: *Immune Endocrine Metabolic Disorders*, **2**(3): 281 – 290.
40. Capron, A., Dessaint, J. P., Capron, M., Ouma, J.H. and Butterworth, A.E. (1997). Immunity to Schistosomiasis: Progress toward vaccine, *Science*, **238**: 1065 – 1072.
41. Capron, A., G. Riveau, M. Capron, and F. Trottein. (2005). Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. *Trends Parasitol.* **21**:143-149.
42. Carvalho – Queiroz, C., Cook, R., Wang, C.C., Correa – Oliveria, R. Bailey, N.A and LoVerde, P.T. (2004). Cross – reactivity of the *Schistosoma mansoni* cytosolic superoxide dismutase, a protective vaccine candidate with host superoxide dismutase and identification of Parasite specific B epitopes. *Infection Immunology*, **72**: 2635 – 2647.
43. Cheesbrough, M. (1981). Medical laboratory manual for Tropical Countries. **Vol. I**. 1st Edition. Stephen Austin Publishers – London.
44. Cheever, A.W. (1969). Quantitative comparison of the intensity of *S. mansoni* infection in man and experimental animals. *Transaction of the Royal Society of Tropical Medicine and Hygiene*, **63**:781-795.
45. Cheever, A.W., and Andrade, Z.A. (1967). Pathological lesions associated with *Schistosoma mansoni* infection in man. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **61**:626-639.
46. Cheever, A., and Duvall, R.H. (1974). Single and repeated infections of grivet monkeys with *Schistosoma mansoni*, Parasitological and pathological observations over a 31 month period. *American Journal of Tropical Medicine and Hygiene*, **23**: 884-894.
47. Cheever, A., Kuntz, R.E., Myers, B.J., Moore, J.A. and Huang, T.C. (1974). *Schistosomiasis haematobium* in African, hamdryas, and gelada baboons. *America Journal of Tropical Medicine and Hygiene*, **23**:429-448.
48. Chitsulo, L., Enfals, D., Montessor, A. and Savioli, L. (2000). The global status of schistosomiasis and its control. *Acta Tropica*, **77**:41-51.
49. Clarke, J, De Worbuton, A. and Blair, D.M. (1970). The Katayama Syndrome report on outbreak in Rhodesia. *African Journal of Medicine*, **16**:123-126.

50. Cnops L, Tannich E, Polman K, Clerinx J and Van Esbroeck M. (2012). *Schistosoma* real-time PCR as a diagnostic tool for travelers and migrants. *Trop. Med. Int. Health*, **17**(10): 1208-1216.
51. Coulson, P.S.(1997). The radiation attenuated vaccine against schistosomiasis in animal models: Paradigms for a human vaccine. *Advance Parasitology*, **39**: 271-336.
52. Craig, P. S., D. P. McManus, M. W. Lightowlers, J. A. Chabalgoity, H. H. Garcia, C. M. Gavidia, R. H. Gilman, A. E. Gonzalez, M. Lorca, C. Naquira, A. Nieto, and P. M. Schantz (2007). Prevention and control of cystic echinococcosis. *Lancet Infect. Dis.* **7**:385-394.
53. Da'dara, A.A, Skelly, P.J., Wang, M.M., Harn, D.A. (2003). A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following *Schistosoma mansoni* infection. *Parasite Immunol.* **25**:429-437.
54. Da'dara, A.A, Skelly, P.J., Wang, M.M., Harn, D.A. (2001). Immunization with plasmid DNA encoding the integral membrane protein, Sm 23, elicits a protective response against schistosome infection in mice. *Vaccine*, **20**: 359 – 369.
55. Damian, R.T., De La Rosa, M.A., Murfin, D.J., Rawlings, C.A., Weine, P.J. and Xue, Y.P. (1992). Further development of the baboon as a model for acute schistosomiasis. *Memories do Instituto Oswaldo Cruz*, Rio De Janeiro, **87**: 261-269.
56. Damian, R.T., Roberts, M.L., Powell, M.R., Clerk, J.D., Lewis, F.A. and Stivewalt, M.A. (1984). *Schistosoma mansoni* egg granuloma size reduction in challenged baboons after vaccination with irradiated cryo-preserved schistosomula. *Proceedings of the National Academy of Sciences U.S.A.*, **81**:3552-3556.
57. Davis, H.L. (1997). Plasmid DNA expression systems for the purpose of immunization. *Current Opinions in Biotechnology*, **8**: 635-640
58. Dessein, A.J. (2003). The role of lost genetics in determining the outcome of parasite Infection. Proceedings of the British Society for Parasitology spring meeting 6-9 April 2003: Manchester.
59. Doolan, D.L., Hoffman, S.L. (2001). DNA based vaccines against malaria: status and promises of the multi-stage malaria DNA vaccine operation. *International Journal of Parasitology*, **31**(8): 753 – 762.
60. Dunne, D.W.(2003). Factors affecting Schistosomiasis associated hepatosplenomegaly in children and adults. Proceedings of the British Society for Parasitology Spring meeting 6-9 April 2003; Manchester, UK.
61. Dunne,D. W., and Doenhoff, M. J.(1983). *Schistosoma mansoni* egg antigens and hepatocyte damage in infected T-cell deprived mice. *Contributions in Microbiology immunology*, **7**:22-29.
62. Dunne, D.W., Butterworth, A.E., Fullford, A.J., Kariuki H., Langley, J.G., Ouma, J.H., Capron, A., Pierce, R.J., Sturrock, R.F. (1992). Immunity after treatment of human Schistosomiasis. Association between IgE antibodies to adult worm antigens and resistance to re-infection. *European Journal of Immunology*, **22**: 1483 – 1494.
63. Dupre, L., Kreimer, L., Wolowezuk, I. Riveau, G., Capron, A., Loch, C. (2001). Immunostimulatory effect of IL-18 encoding plasmid in DNA vaccination against murine *Schistosoma monsoni* infection. *Vaccine*, **19**: 1373 – 1380.
64. Dupre, L., Poulain - Godefroy, O., Ban, E., Ivanoff, N., Mekranfar, M., Schacht, A.M., Capron, A., Riveau, G. (1997). Intra-dermal immunization of rats with plasmid DNA

- encoding *Schistosoma mansoni* 28KD a glutathione-S-transferase. *Parasite Immunology*, **19** (11) 505 -513.
65. Elliott, D. E. (1996). Schistosomiasis. Pathophysiology, Diagnosis and Treatment. *Gastroenterology Clinical, North America*, **25**(3): 599-625.
66. Fan, J., X. Gan, W. Yang, L. Shen, D. P. McManus, and P. J. Brindley. (2003). A *Schistosoma japonicum* very low-density lipoprotein-binding protein. *Int. J. Biochem. Cell. Biol.* **35**:1436-1451.
67. Farah, I.O. and Nyindo, M. (1996). *Schistosoma mansoni* induces in Kenyan baboons novel intestinal pathology that is manifestly modulated by an irradiated cercarial vaccine. *Journal of Parasitology*, **82**(4): 601-607.
68. Farah, I.O., Kariuki, T.M., King, C.L. and Hau, J. (2001). An overview of animal models in experimental schistosomiasis and refinements in the use of non-human primates. *Laboratory Animals*, **35**: 205-212.
69. Farah, I.O., Nyindo, M., Suleiman, M.A., Kariuki, T.M., Blanton, R.E., Elson, L.H. and King, C.L. (1997). *Schistosoma mansoni* development and modulation of the granuloma after multiple exposures in the baboon (*Papio cynocephalus anubis*). *Experimental Parasitology*, **86**:93-101.
70. Farah, I.O., Kariuki, T.M., Nyindo, M., Blanton, R.E. and King, C.L. (2000). Repeated exposure induces periportal fibrosis in *Schistosoma mansoni* – infected baboons. Role of TGF-beta and IL-4. *Journal of Immunology*, **164**: 337-343.
71. Fallon, P. G., Richardson, E. J., Mckenzie, G.J., and Mckenzie, A.N.(2000). Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. *Journal of Immunology*, **164**: 2585-2591.
72. Feldmeier, H. and Poggensee, G. (1993). Diagnostic technique in schistosomiasis control. A review. *Acta Tropica*, **52**:205-220.
73. Fonseca CT, Carvalho GB, Alves CC and Teieira de Melo T. (2012). *Schistosoma* Tegument Proteins in vaccine and diagnosis Development: An update. *Journal of Parasitology Research*. **2012**: 1-8.
74. Fonseca, C. T., C. F. Brito, J. B. Alves, and S. C. Oliveira. (2004). IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa *Schistosoma mansoni* fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. *Vaccine*, **22**:503-510.
75. Fulford, A.J.C., Webster, M., Ouma, J.H., Kimani, G. and Dunne, D.W. (1999). Puberty and age-related changes in susceptibility for *Schistosoma* infection. *Parasitology Today*, **14**: 23-26.
76. Gan, Y., Y. E. Shi, L. Y. Bu, C. X. Ning, and H. G. Zhu. (2005). Vaccination of mice with recombinant nucleic acid vaccine encoding the integral membrane protein Sj23 and cytokine IL-12 elicits specific immune responses against *Schistosoma japonicum*. *Zhonghua Yi Xue Za Zhi*, **85**:193-198.
77. Garmory, H.S., Katherine, A.B. and Richard, W.T. (2003). DNA Vaccines: improving expression of antigens. *Genetic vaccines and therapy*, **1**:2-17.
78. Gressner, J.E., Heiken, H. and Tamm, A. (1998). The IgG Fc receptor family. *Annals of Haematology*, **76**: 231 – 248.
79. Gryseels, B., K. Polman, J. Clerinx, and L. Kestens. (2006). Human schistosomiasis. *Lancet*, **368**:1106-1118

80. Gurunathan, S., Klinman, D.M. and Seder, R.A. (2000). DNA vaccines: immunology, application and optimization. *Annual Review of Immunology*, **18**: 7-9.
81. Gurunathan, S., Prission, C., Sacks, D.L., Seder, R.A. (1998). Vaccine requirement for sustained cellular immunity to an intracellular parasitic infection. *Nature Medicine*, **4**: 1409 – 1415.
82. Hafalla, J.C. Alamar, J.G., Acosta, L.P., Dunne D.W., Pamirez, B.L., Santiago, M.L. (1999) Molecular identification of a 21.7KDA *Schistosoma japonicum* antigen a target of human IgE response. *Molecular Biochemistry of Parasitology*, **98** (1): 157- 161.
83. Hagan, P (1992). Re-infection, exposure and immunity in human schistosomiasis. *Parasitology Today*, **8**:12-16.
84. Hamed, MA and Hetta, MA.(2005). Efficacy of Citrus reticulata and Mirazid in treatment of *S. mansoni*. *Memories do Instituto Oswaldo Cruz*, **100**: 771-778.
85. Hanem, M.A., Mohmoud, H.R., Tavela, S.A.S., Eliab, E.M.D. and Ahamed, A.S. (2006). DNA immunization with the genes Encoding Sm 21.7 protein protects mice against *Schistosoma mansoni* infection. *Journal of American Science*, **2** (4): 59-69.
86. Highton, R.B. (1974). Schistosomiasis in Health and disease in Kenya. East African literature Bureau (Nairobi) pp. 347-353.
87. Hong, Z., LoVerde, P.T., Hammar, M.L., and Rekosh, D. (1992). *Schistosoma mansoni* Cloning of a complementary DNA encoding a cytosolic Cu/Zn superoxide dismutase and high yield expression of the enzymatically active gene product in *Escherichia coli*. *Experimental Parasitology*, **75**:308-322.
88. Hota-Mitchell, S., A. A. Siddiqui, G. A. Dekaban, J. Smith, C. Tognon, and R. B. Podesta.(1997). Protection against *Schistosoma mansoni* infection with a recombinant baculovirus-expressed subunit of calpain. *Vaccine*, **15**:1631-1640.
89. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF and Bennett JL (1996). Characterization of isolates of *S. mansoni* from Egyptian Villagers that tolerate high doses of Praziquantel. *Am J Trop Med. Hygiene*, **55**:214-218.
90. Jankovic, D., L. Aslund, I. P. Oswald, P. Caspar, C. Champion, E. Pearce, J. E. Coligan, M. Strand, A. Sher, and S. L. James.(1996). Calpain is the target antigen of a Th1 clone that transfers protective immunity against *Schistosoma mansoni*. *J. Immunol.* **157**:806-814.
91. Jennifer, F.F., Hemal, K.K., and Stephen, T.M.(2005). Human schistosomiasis and anaemia; the relationship and potential mechanisms. *Trends in Parasitology*, **21**: 386-392.
92. Jourdan, J., and Theron, A. (1987). Larval development, Eggs to Cercariae. In the Biology of *Schistosoma*: From Genes to latrines (eds. Rollinson, D. and Simpson, A.J.) pp 83-114. Academic Press, London.
93. Kallestrup, P., R. Zinyama, E. Gomo, A. E. Butterworth, G. J. van Dam, C. Erikstrup, and H. Ullum. (2005). Schistosomiasis and HIV-1 infection in rural Zimbabwe: implications of coinfection for excretion of eggs. *J. Infect. Dis.* **191**:1311-1320.
94. Karmakar S; Zhang W; Ahmad G; Torben W; Alam MU; Le L; Damian RT; Wolf RF; White GL; Carey DW; Carter D; Reed SG; Siddiqui AA. (2014). Cross-species protection: *S. mansoni* Sm-p80 vaccine confers protection against *S. haematobium* in hamsters and baboons. *Vaccine*. **32(11)**: 1296-1303 (ISSN: 1873-2518)
95. Kariuki, T.M., and Farah, I.O. (2005). Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model. *Parasite Immunology*, **27**: 281-288.

96. Kassim, O. and Gilberton, M .H. (1976). Hatching of *Schistosoma mansoni* eggs and observation on motility of miracidia. *Journal of Parasitology*, **62**:715-720.
97. Katz, N., Cheever, A. and Pellergrino, J. (1972). A simple device for quantitative thick smear technique in Schistosomiasis mansoni. *Revista do instituto de Medicina Tropical de Sao Paulo*, **14**:397-400.
98. King, C.L. (2001). Initiation and regulation of disease in schistosomiasis. In Schistosomiasis. Volume 3. A.A.F. Mohmoud, Ed. Imperial College Press, London. pp 213-236.
99. King, C.L. and Mohmoud, A.A.F (1998). *Schistosoma* and other trematodes. In infectious diseases, pp 2475-2481. Edited by S.L. Gorbeach, J.G. Bartlett and Blacklow, N.R. Philadelphia: WB. Saunders.
100. King, C.L., K. Dickerman, and D.J. Tisch (2003). Re-gauging the cost of schistosomiasis: a meta-analysis of disability related outcomes in endemic populations. *American Journal of Tropical Medicine and Hygiene*, **69**:513-526.
101. Klump, R.K., and Chu, K.Y. (1987). Focal mollusciding an effective way to augment chemotherapy of Schistosomiasis. *Parasitology Today*, **3**: 74-76.
102. Knox, D.P. (2010). Parasite vaccines: Recent Progress in, and Problems Associated with their Development. *The open infectious Disease Journal*, **4**: 63-73.
103. Koukounari, A., Fenwick, A., Whawell, S., Kabaterene, N., Kazibwe , F., Tukattebwa, E.M. and Stothard, J. R.(2006). Morbidity indicators of *S. mansoni*: Relationship between infection and anaemia in Uganda children and that anaemia shows a significant improvement after chemotherapy. *The American Journal of Tropical Medicine and Hygiene*, **75**: 278-286.
104. Kumagai, T., H. Maruyama, M. Hato, H. Ohmae, Y. Osada, T. Kanazawa, and N. Ohta.(2005). *Schistosoma japonicum*: localization of calpain in the penetration glands and secretions of cercariae. *Exp. Parasitol.* **109**:53-57.
105. Kuntz, R.E., Myers, B.J., Moore, J.A. and Huang, T.C. (1971). *Schistosoma haematobium*: Experimental infection in capuchin monkey. *Cebus apella*. *Experimental Parasitology*, **29**: 33-41.
106. Kusel, J.R. and Hagan, P. (1999). Praziquantel – its use, cost and possible development of resistance (News). *Parasitology Today*, **15**:352-354.
107. Lambertucci, J.R., Serufo, J.C., Gerspacher-Lara, R., Rayes, A.A.M., Teixcira, R., Nobre, V. and Antunes, C.M.F. (2000). *Schistosoma mansoni*. Assessment of morbidity before and after control. *Acta Tropica*, **77**: 101-109.
108. Lanar, D. E., E. J. Pearce, S. L. James, and A. Sher. (1986). Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice. *Science*, **234**:593-596.
109. Leenstra, T., L. P. Acosta, H. W. Wu, G. C. Langdon, J. S. Solomon, D. L. Manalo, L. Su, M. Jiz, B. Jarilla, A. O. Pablo, S. T. McGarvey, R. M. Olveda, J. F. Friedman, and J. D. Kurtis. (2006). T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with *Schistosoma japonicum*. *Infect. Immun.* **74**:370-381.
110. Lenzi, H.L., Sobral, C.L., and Lenzi, J.A. (1987). In vivo kinetics of eosinophils and mast cells in experimental Schistosomiasis. *Memories do Instituto Oswaldo Cruz, Rio de Janeiro*, **82**: 67-76.

111. Li, Y. S., G. Raso, Y. Zhao, H. K. He, M. Ellis, and D. P. McManus. (2007). Predicted impact of large water management projects on schistosomiasis transmission and control in the Dongting Lake Region, China. *Emerg. Infect. Dis.* **13**:973-979.
112. Loukas, A., Jones m.K., King L.T., Brindley P.T and McManus, D.P. (2001). Receptor for Fc on the surface of schistosomes. *Infection and Immunity*, **67**: 6565 – 6571.
113. Loukas, A., M. Tran, and M. S. Pearson. (2007). Schistosome membrane proteins as vaccines. *Int. J. Parasitol.* **37**:257-263.
114. LoVerde, P.T. (1998). Do antioxidants play a role in *Schistosoma* host-parasite interactions? *Parasitology Today*, **14**:109-113.
115. LoVerde, P.T., Carvallo-Queiroz, C. and Cook, R (2004). Vaccination with antioxidant enzymes confers protective immunity against challenge infection with *Schistosoma mansoni*. *Memories do Instituto Oswaldo Cruz*, Rio de Janeiro, **99**: 37-43.
116. Liu, J. M., X. Z. Cai, J. J. Lin, Z. Q. Fu, G. Z. Yang, F. H. Shi, Y. M. Cai, W. Shen, M. G. Taylor, and X. F. Wu. (2004). Gene cloning, expression and vaccine testing of *Schistosoma japonicum* SjFABP. *Parasite Immunol.* **26**:351-358.
117. Lyons, M.K. (1978). The Biology of Helminthes Parasites. Institute of Biology's Studies in Biology No. 102. Edward Anorld Publisher. The Camelot Press, Southmpton, U.K.
118. Maizels, R.M, Bundy, D.A., Selkirk, M.E., Smith, D.F., and Anderson R.M. (1993). Immunological modulation and evasion by helminthes parasites in human populations. *Nature*, **365**: 797-805.
119. McManus, D. P. (2005). Prospects for development of a transmission blocking vaccine against *Schistosoma japonicum*. *Parasite Immunol.* **27**:297-308.
120. McManus, D.P. (2000). DNA vaccine against Asian Schistosomiasis the story unfolds. *Institute Journal of Parasitology*, **30**: 265 – 271.
121. McManus, D.P., Liu, S., Song, G., Xu, Y., Wong, J.M. (1998).The vaccine efficacy of native paramyosin (Sj-97)against Chinese *Schistosoma japonicum*. *International Journal of Parasitology*, **28**(11):1739-1742.
122. Mei, H., Thakur, A., Schwartz, J and LoVerde, P.T. (1996). Expression and characterization of glutathione peroxidase and the human blood fluke, *Schistosoma mansoni*. *Infection and Immunology*, **64**: 4299-4306.
123. Mei, H., and LoVerde, P.T.(1995). *Schistosoma mansoni*. Cloning the gene encoding glutathione peroxidase. *Experimental Parasitology*, **80**: 319- 322.
124. Mei, H. and LoVerde, P.T. (1997). *Schistosoma mansoni* the development regulation and immuno-localization of antioxidant enzymes. *Experimental Parasitology*, **86**: 69-78.
125. Miller, J.H.(1960). The dog face baboon (*Papio doguera*), A primate reservoir host of *Schistosoma mansoni* in East Africa. *Journal of Parasitology*, **45**:22-28.
126. Mitchinson, N and Oliviera, D. (1986). Chronic infection as a major force in the evolution of the suppressor T-cell system. *Parasitology Today*, **2**:312-313.
127. Mohammed, M.M., Shalaby, K.A., LoVerde, P.T. and Karim, A.M. (1998). Characterization of Sm 20.8, a member of a family of Schistosome tegumental antigens. *Molecular and Biochemical Parasitology*, **96**: 15-25.
128. Mola, P.W., Farah, I.O., Kariuki, T.M., Nyindo, M., Blanton, R.E. and King, C.L. (1999). Cytokine control of the granulomatous response in *Schistosoma mansoni* infected baboons: role of exposure and treatment. *Infection and Immunology*, **67**: 6565-6571.
129. Moore, D.L., Grove D.L and Warren, K.S. (1976).*Schistosoma mansoni* egg granuloma. Quantitation of populations. *Journal of Pathology*, **121**:41-50.

- 1133 130. Mousa, A.H. (1967) Clinicopathological aspects of hepatosplenic bilharziasis. In Mostoff,
1134 F.K. Edition. Bilharziasis, Berlin Springer- Verlag, 15 – 29.
- 1135 131. Myers, B.J., Kuntz, R.E., Huang, T.Y.C, and Moore, R.A. (1970).Urinary bladder
1136 involvement in the larger Presbyters infected with *Schistosoma haematobium*
1137 (Bilharz 1852) Weinland, 1858, *Proceeding of the Helminthological Society of*
1138 *Washington*, **37**: 189- 192.
- 1139 132. Nagi, M.A. M., Kumar, A., Mubarak, J.S., and Bamashmoos S.A. (1999).
1140 Epidemiological. Clinical and hematological profile of schistosomiasis in Yemen.
1141 *Eastern Mediterranean Health Journal*, **5**:177-181.
- 1142 133. Nara, T., K. Iizumi, H. Ohmae, O. S. Sy, S. Tsubota, Y. Inaba, A. Tsubouchi, M. Tanabe, S.
1143 Kojima, and T. Aoki. (2007). Antibody isotype responses to paramyosin, a vaccine
1144 candidate for schistosomiasis, and their correlations with resistance and fibrosis in
1145 patients infected with *Schistosoma japonicum* in Leyte, The Philippines. *Am. J. Trop.*
1146 *Med. Hyg.* **76**:384-391.
- 1147 134. Nguyen-Khoa, S.; Smith, L.; Lorenzen, K. (2005). Impacts of irrigation on inland fisheries:
1148 Appraisals in Laos and Sri Lanka. Comprehensive Assessment Research Report 7.
1149 Colombo, Sri Lanka: Comprehensive Assessment Secretariat
- 1150 135. Njenga, M.N., Farah, O.I., Muchemi, G.K., Nyindo, M. (1998). Periportal fibrosis of
1151 liver due to natural or experimental infection with *Schistosoma mansoni* occurs in the
1152 Kenyan baboons. *Annals of Tropical Medicine and Parasitology*, **92 (2)**: 187-193.
- 1153 136. Nyindo, M and Farah, I, O. (1999). The baboon as a non-human private model of human
1154 Schistosome infection, *Parasitology Today*, **15**: 478 – 482.
- 1155 137. Nyindo, M., Kariuki, T.M., Mola, P., Farah, I.O., Elson, L., Blanton, R.E. and King, C.L.
1156 (1999). Role of adult worm antigen-specific immunoglobulin E in acquired immunity
1157 to *Schistosoma mansoni* infection in baboons. *Infection and Immunology*, **67**: 636-642.
- 1158 138. Omer-Ali, P., Smithers, S.R., Bickle, Q., Philips, S.M., Harn, D. and Simpson,
1159 A.A.J.(1988).Analysis of the anti-*Schistosoma mansoni* vaccine. *Journal of Parasitology*,
1160 **57**: 1138 – 1140.
- 1161 139. Osada, Y., T. Kumagai, M. Hato, T. Suzuki, M. El-Malky, H. Asahi, T. Kanazawa, and N.
1162 Ohta. (2005). Establishment of *Schistosoma japonicum* calpain-specific mouse T cell
1163 hybridomas and identification of a T cell epitope that stimulates IFNgamma production.
1164 *Vaccine*, **23**:2813-2819.
- 1165 140. Pearce, E.J.(2003). Progress towards a vaccine for schistosomiasis. *Acta Tropica*, **86**: 309-
1166 313.
- 1167 141. Pearce, E.J. and MacDonald, A.S. (2002). The immunobiology of schistosomiasis. *Nat. Rev.*
1168 *Immunol.* **2**:499-511.
- 1169 142. Pearce, E. J., S. L. James, S. Hieny, D. E. Lanar, and A. Sher. (1988). Induction of
1170 protective immunity against *Schistosoma mansoni* by vaccination with schistosome
1171 paramyosin (Sm97), a nonsurface parasite antigen. *Proc. Natl. Acad. Sci. USA* **85**:5678-
1172 5682.
- 1173 143. Pikes, E. G.(1987). Engineering against Schistosomiasis/bilharzias. Guidelines towards
1174 control of the disease. London and Basingstoke, Macmillan.
- 1175 144. Pittella, J.E. and Lana-Peixoto, M.A. (1981). Brain involvement in Hepatosplenic
1176 *Schistosoma mansoni*. *Brain*, **104**:621-632.

- 1177 145. Porchet, E., A. McNair, A. Caron, J. P. Kusnier, K. Zemzoumi, and A. Capron. (1994).
 1178 Tissue expression of the *Schistosoma mansoni* 28 kDa glutathione S-transferase.
 1179 *Parasitology* **109**:565-572.
- 1180 146. Ralma, A. and El-Sheikh, M. (1985). The katayama syndrome in Saudi. *Journal of*
 1181 *Tropical Medicine and Hygiene*, **88**(5): 319-323.
- 1182 147. Ramsay, A.J., Kent. S.J., Strugnell, R.A., Suhrbier A., Thomson, S.A., Ramshaw, I.A.
 1183 (1999). Genetic vaccination strategies for enhanced cellular, humoral and mucosal
 1184 immunity. *Immunology Review*, **171**: 27 – 44.
- 1185 148. Ramaswamy, K. and Kumar, P. (2000). A role for parasite – induced PGE 2 in IL- 10
 1186 mediated host immuno regulation by skin stage schistosomula of *Schistosoma mansoni*.
 1187 *Journal of Immunology*, **165**: 4567- 4574.
- 1188 149. Richter, J. (2003). The impact of chemotherapy on morbidity due to schistosomiasis. *Acta*
 1189 *Tropica*, **86**: 161-183.
- 1190 150. Saconato, H., and Atallah, A. (2000). Interventions for treating *Schistosoma mansoni*.
 1191 Assessment of morbidity before and after control. *Acta Tropica*, **77**: 101-109.
- 1192 151. Sadun, E. H., Von Lichtenberg, F., and Bruce, J.I. (1966). Susceptibility and comparative
 1193 pathology of ten species of primates exposed to infection with *Schistosoma mansoni*.
 1194 *American Journal of Tropical Medicine and Hygiene*, **15**: 705-718.
- 1195 152. Seder, R.A. and Guranathan, S. (1999). DNA vaccines; designer vaccines for the twenty
 1196 first century. *English Journal of Medicine*, **34**:277-278.
- 1197 153. Shalaby, K.A., Yin, L., Thakur, A., Christen, L.A., Niles, E.G., LoVerde, P.T. (2003).
 1198 Protection against *Schistosoma mansoni* utilizing DNA vaccination with genes
 1199 encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing peroxide
 1200 dismutase, and glutathione enzymes. *Vaccine*, **22**:130-136.
- 1201 154. Shuxian, L., Guangchem, S., Yxin, X., McManus, D.P., Hotez, P.J. (1998). *Progress in*
 1202 *the Mediterranean Health Journal*, **5**: 177 – 181
- 1203 155. Siddiqui, A. A., T. Phillips, H. Charest, R. B. Podesta, M. L. Quinlin, J. R. Pinkston, J. D.
 1204 Lloyd, J. Pompa, R. M. Villalovos, and M. Paz. (2003). Enhancement of Sm-p80 (large
 1205 subunit of calpain) induced protective immunity against *Schistosoma mansoni* through
 1206 co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. *Vaccine*,
 1207 **21**:2882-2889.
- 1208 156. Siddiqui, AA , Karmakar S; Zhang W; Ahmad G; Torben W; Alam MU; Le L; Damian RT;
 1209 Wolf RF; White GL; Carey DW; Carter D; Reed SG. (2014). Therapeutic vaccine:
 1210 Killing of established adult schistosome parasites in chronically infected baboons
 1211 following vaccination with Sm-p80 vaccine. *J. Infect. Dis.* **209**(12): 1929-1940.
- 1212 157. Siddiqui, AA., Y. Zhou, RB. Podesta, SR. Karcz, C.E. Tognon, GH. Strejan, G A. Dekaban,
 1213 and M.W. Clarke. (1993). Characterization of Ca(2+)-dependent neutral protease
 1214 (calpain) from human blood flukes, *Schistosoma mansoni*. *Biochim. Biophys. Acta*,
 1215 **1181**:37-44.
- 1216 158. Smahel, M. (2002). DNA vaccine. *Caslek Cesk*, **22**(141): 26 -32.
- 1217 159. Smither, D.(1982). Schistosomiasis, Black Well Scientific Publications, Oxford-London.
- 1218 160. Smithers, S.R. and Terry, R.J. (1969). Immunity in schistosomiasis. *Annals of New York*
 1219 *Academy of Sciences*, **160**:695-700.
- 1220 161. Smyth, D., D. P. McManus, M. J. Smout, T. Laha, W. Zhang, and A. Loukas.(2003).
 1221 Isolation of cDNAs encoding secreted and transmembrane proteins from *Schistosoma*
 1222 *mansoni* by a signal sequence trap method. *Infect. Immun.* **71**:2548-2554.

- 1223 162. Soisson , L.A., Reid G.D.F. Farah, 1.0. Nyindo, M., Strand, M (1993). Protective
 1224 Immunity in baboons vaccinated with a recombinant antigen or radi-
 1225 ation attenuated cercariae is antibody dependent. *Journal of Immunology and Hygiene*,
 1226 **151**: 4782-4789.
- 1227 163. Stelma, F.F., Talla, I., Son, S., Kongs, A., Niang, M., Polman, K., Deelder, A.M. and
 1228 Gryseels, B. (1995). Efficacy and side effects of Praziquantel in an epidemic focus of
 1229 *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene*, **53**:167-
 1230 170.
- 1231 164. Stevens, A., Lowe, S.J. and Young B. (2002). Wheaters Basic Histopathology. 4th Edition.
 1232 Churchill Livingstone Publisher.
- 1233 165. Sturrock, R.F. (2001). The Schistosomes and their intermediate hosts. In
 1234 Schistosomiasis (Mahmed A.A. P. Ed) Imperial College Press.
- 1235 166. Sturrock, R.F. (1986). A review of the use of primates in studying human schistosomiasis.
 1236 *Journal of medical Parasitology*, **15**: 267-279.
- 1237 167. Sturrock, R.F. Cottrell, B.J., Kimani, R. (1984). Observations on the ability of repeated, light
 1238 exposures to *Schistosoma mansoni* cercariae to induce resistance to re-infection in Kenya
 1239 baboon (*Papio anubis*). *Parasitology*, **88**: 505 –514.
- 1240 168. Sturrock, R.F., Butterworth, A.E., Houta, V., Karamsadar, S.D. and Kimani, R. (1978).
 1241 *Schistosoma mansoni*. In Kenya baboon (*Papio anubis*) the development and
 1242 predictability of resistance to homologous challenge. *Transaction of Royal Society of*
 1243 *Tropical Medical Hygiene*, **72**:251-261.
- 1244 169. Sturrock, R.F., Butterworth, A.E., and Houba, V. (1976). *Schistosoma mansoni* in the
 1245 baboon (*Papio anubis*): Parasitological responses of Kenyan baboons in different
 1246 exposures of local parasite strain. *Parasitology*, **73**:239 – 252.
- 1247 170. Tendler, M., C. A. Brito, M. M. Vilar, N. Serra-Freire, C. M. Diogo, M. S. Almeida, A. C.
 1248 Delbem, J. F. Da Silva, W. Savino, R. C. Garratt, N. Katz, and A. S. Simpson. (1996). A
 1249 *Schistosoma mansoni* fatty acid-binding protein, Sm14, is the potential basis of a dual-
 1250 purpose anti-helminth vaccine. *Proc. Natl. Acad. Sci. USA* **93**:269-273.
- 1251 171. Tran, M. H., M. S. Pearson, J. M. Bethony, D. J. Smyth, M. K. Jones, M. Duke, T. A. Don,
 1252 D. P. McManus, R. Correa-Oliveira, and A. Loukas. 2006. Tetraspanins on the surface of
 1253 *Schistosoma mansoni* are protective antigens against schistosomiasis. *Nat. Med.* **12**:835-
 1254 840
- 1255 172. Tuteja, R. (1999). DNA vaccines: a ray of hope. Critical review. *Biochemistry and*
 1256 *Molecular Biology*, **34**(1): 1-24.
- 1257 173. Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Felguer, P.L.,
 1258 Dwarla, V.J. Grombowski, S.H., Deck, R.R., Dewitt, C.M., Friedman, A.
 1259 (1993). Heterologous protection against influenza by injection of DNA encoding a viral
 1260 protein. *Science*, **19** (259): 1745 -1749.
- 1261 174. van der Werf, M.J., De Vlas, S.J., Brooker, S., Looman, C.W., Nagelkerke, N.J., Habbema,
 1262 J.A. and Eugels, D. (2003). Quantification of clinical morbidity associated with
 1263 schistosome infections in sub-Sahara Africa. *Acta Tropica*, **86**: 125-139.
- 1264 175. Varaldo, P. B., L. C. Leite, W. O. Dias, E. N. Miyaji, F. I. Torres, V. C. Gebara, G. R.
 1265 Armoa, A. S. Campos, D. C. Matos, N. Winter, B. Gicquel, M. M. Vilar, J. McFadden,
 1266 M. S. Almeida, M. Tendler, and D. McIntosh. 2004. Recombinant *Mycobacterium*
 1267 *bovis* BCG expressing the Sm14 antigen of *Schistosoma mansoni* protects mice from
 1268 cercarial challenge. *Infect. Immun.* **72**:3336-3343.

- 1269 176. Villinger, F., Bostic, P., Mayne, A., King, C.L., Genain, C.P., Weiss, W.R., and Ansan, A.A.
 1270 (2001). Cloning, sequencing, and homology analysis of non-human primate Fas/Fas-
 1271 ligand Co-stimulatory molecules. *Immunogenesis*, **53**:315-328.
- 1272 177. Waite, G.J., Yang, W., Scott, J.C., McManus, D.P., Kalina, B.H. (1997). DNA - based
 1273 vaccination using *Schistosoma japonicum* (Asian blood-fluke) genes. *Vaccine*, **15** (8):
 1274 546 – 548.
- 1275 178. Warren, S.K. (1966). Pathogenesis of “clay-pipe stem cirrhosis” in mice with chronic
 1276 *Schistosoma mansoni*, with a note on the longevity of schistosomes. *American Journal*
 1277 *of Pathology*, **49**: 477-482.
- 1278 179. Warren, S.K., (1984). Schistosomiasis. In; Weatherall, D.J., Ledingham, J.G.G., Warrel,
 1279 D.A., edition. Oxford textbook of medicine, Oxford University press.
- 1280 180. Woodruff, A.W. (1966). Anemia in patients with Schistosomiasis and gross
 1281 splenomegaly. *Transactions of the Royal Society of Tropical Medicine*
 1282 *and Hygiene*, **60**: 343-351.
- 1283 181. Woolhouse, M.E.J., Taylor, P., Matanhire, D. and Chandiwana, S.K. (1991). Acquired
 1284 immunity and epidemiology of *Schistosoma haematobium*. *Parasitology Today*, **8**: 12-
 1285 16.
- 1286 182. Wright, M. D., A. M. Melder, K. M. Davern, and G. F. Mitchell. (1991). Serologic
 1287 reactivities of the 23-kDa integral membrane proteins of schistosomes. *J. Immunol.*
 1288 **147**:4338-4342.
- 1289 183. Wu, Z. D., Z. Y. Lu, and X. B. Yu. 2005. Development of a vaccine against *Schistosoma*
 1290 *japonicum* in China: a review. *Acta Trop.* **96**:106-116.
- 1291 184. Wyler, D.J. and Telebian, P (1997). A quantitative assay to detect circulating fibrosin and
 1292 its application in experimental schistosomiasis. *American Journal of Tropical*
 1293 *Medicine and Hygiene*, **55**:66-70.
- 1294 185. Wynn, T.A. (1996), Development of an anti-pathology vaccine for schistosomiasis.
 1295 *Annual of New York Academic of Science*, **797**:191-195.
- 1296 186. Xu, C. B., C. Verwaerde, H. Gras-Masse, J. Fontaine, M. Bossus, F. Trottein, I.
 1297 Wolowczuk, A. Tartar, and A. Capron. (1993). *Schistosoma mansoni* 28-kDa glutathione
 1298 S-transferase and immunity against parasite fecundity and egg viability. Role of the
 1299 amino- and carboxyl-terminal domains. *J. Immunol.* **150**:940-949.
- 1300 187. Yang, W., Jackson, D.C., Zeng, Q. and McManus, D.P. (2000). Multi-epitope Schistosome
 1301 vaccine candidates tested for protective immunogenicity in mice. *Vaccine*, **19**:102-113.
- 1302 188. Yang, W., Waite, G.J., McManus, D.P. (1995). Antibodies to *Schistosoma japonicum*
 1303 (Asian flukes) paramyosin induced by nucleic acid vaccination. *Biochemica Biophysica*
 1304 *Research Communication*, **26** (3): 1029 –1039.
- 1305 189. Yole, D.S., Pemberton, R., Reid, G.D., Wilson, R.A. (1996). Protective immunity to
 1306 *Schistosoma mansoni* induced in the olive baboon, *Papio anubis*, by irradiated
 1307 cercariae vaccine. *Parasitology*, **112**: 37 – 46.
- 1308 190. Yu, X. L., Y. K. He, T. Xiong, Y. Q. Zhao, M. Z. Shi, J. Zhou, Z. C. Liu, X. S. Luo, X. Fu,
 1309 H. B. He, D. A. Harn, and Y. S. Li. (2006). Protective effects of co-immunization with
 1310 SjCTPI-Hsp70 and interleukin-12 DNA vaccines against *Schistosoma japonicum*
 1311 challenge infection in water buffalo. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong*
 1312 *Bing Za Zhi* **24**:433-436.

- 1313 191. Zhang, Y., Taylor, M.G., Johansen, M.V., Bickle, Q.D. (2001). Vaccination of mice
1314 with a cocktail DNA vaccine induces a Th-1 type immune response and partial protection
1315 against *Schistosoma japonicum* infection. *Vaccine*, **12**: 724 – 730.
- 1316 192. Zhang W; Ahmad G; Torben W; Le L; Damian RT; Wolf RF; White GL; Chavez-Suarez
1317 M; Podesta RB; Kennedy RC and Siddiqui, AA (2010). Sm-p80 based DNA vaccine
1318 provides baboons with levels of protection against *S. mansoni* infection comparable to
1319 those achieved by irradiated cerarial vaccine. *J. Infect. Dis.* **201(7)**: 1105-1112.
- 1320 193. Zhao, S., Y. C. Zhu, D. A. Harn, J. Si, J. G. Ren, X. R. Yin, W. He, Y. S. Liang, M. Xu, and
1321 Y. L. Xu. (2005). Enhancement of the protective effect of SjC23 DNA vaccine against
1322 *Schistosoma japonicum* infection by immunostimulatory sequence. *Zhongguo Ji Sheng*
1323 *Chong Xue Yu Ji Sheng Chong Bing Za Zhi* **23**:1-5.
- 1324 194. Zhou, S., Lin, S., Song, G., Xu, Y. (1999). Studies on the features of protective immune
1325 response induced by recombinant SJC 26 GST of *Schistosoma japonicum*. *Zhongguo*
1326 *Ji sheng chong Xue YU Ji sheng ching bing Za Zhi*, **17 (2)** 74 – 77.
- 1327 195. Zhu, Y., J. Ren, A. Da'dara, D. Harn, M. Xu, J. Si, C. Yu, Y. Liang, P. Ye, X. Yin, W. He,
1328 Y. Xu, G. Cao, and W. Hua. (2004). The protective effect of a *Schistosoma japonicum*
1329 Chinese strain 23 kDa plasmid DNA vaccine in pigs is enhanced with IL-12. *Vaccine*
1330 **23**:78-83.
- 1331 196. Zhu, Y., J. Si, D. A. Ham, C. Yu, W. He, W. Hua, X. Yin, Y. Liang, M. Xu, and R. Xu.
1332 (2002). The protective immunity produced in infected C57BL/6 mice of a DNA vaccine
1333 encoding *Schistosoma japonicum* Chinese strain triose-phosphate isomerase. *Southeast*
1334 *Asian J. Trop. Med. Public Health*, **33**:207-213.